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Complex regional pain syndrome (CRPS) is a chronic pain condition that may 
occur after injury or trauma to a limb. The underlying pathophysiology of CRPS 
is largely undetermined, although CRPS patients commonly present with a 
persisting inflammatory response in the early stage of the condition and over-
express the α-1 adrenergic receptor (α-1AR) on nociceptors and keratinocytes in 
the affected limb. In other chronic inflammatory conditions, increased α-1AR 
mRNA expression in peripheral blood mononuclear cells (PBMCs) has been 
shown, and is thought to contribute to persisting inflammation. The α-1AR are 
expressed on a range of cells, including nerve, smooth muscle, skin and immune 
cells, and bind to adrenaline and noradrenaline released after activation of the 
sympathetic nervous system. The aims of this project were to examine the 
mRNA expression of α-1AR subtypes (α-1A, α-1B and α-1D) by qPCR in 
PBMCs isolated from fractionated blood of CRPS patients, and to quantify the 
percentages of various PBMC subpopulations compared to healthy controls. 
Subpopulations of PBMCs were determined by flow cytometry using a panel of 
fluorescent antibodies that identified CD4+ T cells, CD8+ T cells, CD4+ CD8+ T 
cells, CD4+ CD25+ T cells, CD8+ CD25+ T cells, B cells, natural killer (NK) 
cells, NKT cells, and subsets of monocytes. No differences in expression of α-
1AR subtypes in PBMCs of CRPS patients were found when compared to 
healthy controls. However, a significant increase in the concentration of total 
PBMCs isolated per mL of blood in CRPS patients and a shift from CD16- to 
CD16+ monocyte subpopulations was identified when compared to healthy 
 iv 
controls. These results show there is an inflammatory component to CRPS and 
provide preliminary evidence that the persisting inflammation in CRPS patients 
may originate from over-proliferation of PBMC progenitors in the bone marrow, 
which is sympathetically modulated by α-1AR, and/or an expansion of other 
PBMC cell types that were not examined in this project.  
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1. Literature Review 
1.1. Introduction 
Complex regional pain syndrome (CRPS) describes a group of painful disorders 
that may develop after limb trauma or nerve lesion. Although heavily defined by 
severe pain which may be either spontaneous or stimulus-induced, patients 
experience a range of inflammation, sensory-motor disturbances and autonomic 
signs and symptoms involving abnormal blood flow, sweating, oedema and 
trophic changes of the affected extremity (Geertzen et al., 1998). These 
symptoms are representative of an impaired sympathetic nervous system (SNS) 
and an inflammatory response that can persist for as long as eighteen months 
(Marchand et al., 2005). In an attempt to accommodate the varying symptoms, 
patients are categorised into one of two types. Type I CRPS, formerly known as 
reflex sympathetic dystrophy (RSD), describes disease states without apparent 
nerve injury, whereas type II CRPS (formerly known as causalgia) groups 
patients with damage to a peripheral nerve trunk (Merksey and Bogduk, 1994; 
Borchers and Gerschwin, 2014).  
 
Studies have suggested a link between the SNS and inflammation in the 
pathogenesis of CRPS, with several observations showing an increase in density, 
or responsiveness, of α-1 adrenergic receptors (α-1AR) in sensory nerve fibres 
and skin cells of CRPS patients (Dawson et al., 2011; Drummond et al., 2014a; 
Drummond et al., 2014b). Increased α-1AR on pain-signalling neurons 
(nociceptors) are subject to sensitisation by circulating catecholamines, likely 
contributing to SNS malfunction, and a network of pro-inflammatory mediators 
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during the inflammatory response that likely stimulate the release of 
neuropeptides (Borchers and Gerschwin, 2014; Birklein and Schlereth, 2015). 
These neuropeptides evoke vasodilation and protein extravasation, facilitating 
neurogenic and local inflammation (Birklein et al., 2001a; Lei et al., 2003; 
Schinkel et al., 2006). This suggests α-1AR may facilitate the link between the 
malfunctioning SNS and the inflammatory response of CRPS.  
 
Furthermore, α-1AR mRNA is detectable in human peripheral leukocytes of 
other chronic inflammatory disease states such as asthma and rheumatoid 
arthritis. In this case, α-1AR is functionally linked to the release of pro-
inflammatory cytokines from these cells when stimulated with adrenergic ligands 
such as the catecholamine noradrenaline, or the α-1AR agonist phenylephrine 
(Ricci et al., 1999; Szentivanyi et al., 1979; Wahle et al., 1999; Heijnen et al., 
1996). As α-1AR is abnormally expressed on keratinocytes and nociceptors in 
CRPS, and due to the evidence of an aberrant inflammatory response, evidence 
that CRPS leukocytes express α-1AR could provide further evidence of an SNS 
association with persisting inflammation in CRPS (Figure 1.1).  
 
Therefore, the aims of this project were to compare the expression of α-1AR 
mRNA in leukocytes of CRPS patients to that of healthy non-CRPS controls, and 
to compare the composition of different leukocytes in CRPS to non-CRPS 
individuals, as a shift in distribution or numbers of leukocytes could provide 
further evidence for a role of inflammation in CRPS.  
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This chapter will provide an introduction to the α-1AR inflammatory 
pathogenesis in CRPS that involves the following concepts: i) the clinical 
features of CRPS including symptoms and difficulties in diagnosis; ii) an 
overview of α-1AR and their main physiological functions; iii) an overview of 
the inflammatory response describing the roles of different cell types and 
mediators in inflammation; iv) the role of α-1AR signalling in inflammation, 
describing their potential roles in regulating the immune system and 
inflammatory disease states, and; v) the role of inflammation in the pathogenesis 
of CRPS and how this could be regulated by α-1AR signalling.  
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Figure 1.1: Concept diagram describing the role of α-1AR in CRPS. After injury, an inflammatory 
response is initiated to restore homeostasis by eliminating any infectious or noxious agents and promoting 
healing and repair. This is achieved through production of inflammatory mediators and migration of 
leukocytes to the site of injury. Stimulation of α-1AR on leukocytes by catecholamines and sensitisation by 
cytokines in CRPS may facilitate persisting inflammation, whereas non-CRPS healthy leukocytes do not 
express α-1AR and can regain homeostasis.  




1.2. The clinical presentation of complex regional pain syndrome  
1.2.1.  Signs and symptoms 
The symptoms of CRPS are multifarious and vary substantially between patients, 
with some patients experiencing heightened levels of one symptom but not of 
another that may be elaborated in another patient. Often, patients also experience 
a change in symptoms throughout the course of disease. These symptoms can be 
grouped into five categories: i) pain and sensitivity; ii) motor disorders; iii) 
autonomic symptoms; iv) trophic changes and; v) body perception disturbances 
(GalveVilla et al., 2016).  Symptoms are mostly confined to the extremities, 
however; in severe cases these symptoms can spread from the affected nerve 
region to an unaffected region, proximally or contra-laterally (GalveVilla et al., 
2016). There have been few cases where symptoms develop proximally (i.e. in 
the shoulder or the knee) without any other symptoms distally (van Bussel et al., 
2015). In addition, symptoms may also spread to the head and neck (Allen et al., 
1999; Schwartzman et al., 2009). 
 
Pain and sensitivity symptoms include causalgia, allodynia, hyperalgesia and 
hypoalgesia. Causalgia is the term used to describe burning pain in a limb due to 
peripheral nerve damage (Todorova et al., 2012). Most CRPS patients describe 
their pain as a burning or causalgic sensation (Hassantash et al., 2003). Type I 
patients also describe this as a deep tissue localisation such as a dull ache or tear 
(Birklein et al., 2000; Birklein et al., 2001b). Allodynia is a term used to describe 
the provocation of pain by stimuli that would not usually cause pain, whereas 
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hyperalgesia and hypoalgesia are heightened and reduced sensitivity to pain, 
respectively (Gierthmnuhlen et al., 2012).  
 
Motor disturbances include reduced movement due to inhibitory influences of 
pain and oedema, as well as fibrotic contractions that can limit further movement 
during the chronic stages of CRPS (GalveVilla et al., 2016). Some patients 
experience central motor symptoms such as tremors, irregular muscle spasms 
(myoclonus) and/or fixed dystonia-like postures, seen more commonly in CRPS 
type I patients (de Mos et al., 2009b; de Boer et al., 2011). Inappropriate pain 
behavior such as fear-avoidance can lead to prolonged immobilisation of the 
affected limb, resulting in joint stiffness and muscle atrophy (GalveVilla et al., 
2016).  
 
Autonomic symptoms are due to overcompensated vasodilation and 
vasoconstriction. During the acute stages of CRPS, the affected limb usually 
presents as warm, red and swollen (“warm type” CRPS) but may begin to feel 
colder during the course of the disease and into the chronic stages (“cold type” 
CRPS) (Wasner et al., 1999) (Figure 1.2).  Skin temperatures may also fluctuate 
over time dependent upon the environment (Veldman et al., 1993; Birklein et al., 
2000). This may cause patients to develop hyper- or hypohidrosis (increased or 
decreased sweating) and skin colour changes to red or blue when compared to 
the contralateral side (Figure 1.2). Patients often experience oedema and swollen 
limbs during the acute phases of CRPS (GalveVilla et al., 2016).  
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Figure 1.2: Symptoms of CRPS. A) Evidence of trophic changes with the skin appearing shiny; B) 
Inflammation and oedema of the lower extremity. This patient has self-inflicted this oedema using a 
tourniquet; C) Red and swollen fingers depicting autonomic disturbances of the upper extremity and; D) 
Asymmetric sweating of the affected extremity. 
 
Trophic changes include skin that may appear thin and shiny (Figure 1.2A) with 
decreased or increased hair and nail growth, and the nails may become brittle, 
ridged, curved or dull (Gierthmnuhlen et al., 2012; Birklein et al., 2000). Body 
perception disturbances are a less specific symptom of CRPS. They resemble 
typically neglect-like phenomena, with abnormal limb perception in relation to 
size and altered proprioception (GalveVilla et al., 2016).  
 
1.2.2.  Diagnosis  
Complex regional pain syndrome is a heterogeneous disease with a challenging 
diagnosis. Not only are the signs and symptoms extremely variable over time and 
differ between individuals, CRPS can also mimic a localised response to 
infection or trauma. Thus, CRPS diagnosis rests entirely on clinical assessment 
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and is a diagnosis of exclusion. The diagnostic criteria have been carefully 
reviewed and developed by a subgroup of the International Association for the 
Study of Pain (IASP) now known as the CRPS Budapest diagnostic criteria as 
shown in Tables 1.1 and 1.2 (Harden and Bruehl, 2005).  
 
Dichotomous (yes/no) CRPS diagnoses are necessary clinically but do not 
adequately capture the severity, change in condition or variability among 
patients. The continuous CRPS Severity Score (CSS) addresses these issues, 
evolving from the original Budapest criteria, including all 17 diagnostic CRPS 
features shown in Table 1.3. “Self-reported symptoms” are noticed and reported 
by the patient, whereas “signs observed on examination” are reported by the 
physician or health expert examining the patient. Allodynia and hyperpathia 
(exaggerated level of pain to stimuli) are measured by the patients’ response to a 
pinprick and temperature asymmetry is measured with a temperature gauge 
(GalveVilla et al., 2016). The remaining symptoms are examined by observation 
(Harden et al., 2010). The CSS provides a quantitative index of the signs and 
symptoms of CRPS, with a score of 1 given to the presence of each symptom. 
With the CSS, not only are patients dichotomously diagnosed with CRPS, but 
also the severity of the condition can be monitored and defined accordingly 
(Harden et al., 2010). 
 







Table 1.1: IASP Diagnostic Criteria for CRPS (Merskey and Bogduk, 1994). 
CRPS type I CRPS type II 
1. The presence of an initiating noxious 
event, or a cause of immobilisation. 
1. Type II is syndrome that develops after 
nerve injury. Spontaneous pain or allodynia/ 
hyperalgesia occurs and is not necessarily 
limited to the territory of the injured nerve. 
2. Continuing pain, allodynia, or 
hyperalgesia in which the pain is 
disproportionate to any known inciting event. 
2. There is or has been evidence of oedema, 
skin blood flow abnormality, or abnormal 
sudomotor activity in the region of the pain 
since the inciting event. 
3. Evidence at some time of oedema, changes 
in skin blood flow, of abnormal sudomotor 
activity in the region of pain. 
3. This diagnosis is excluded by the existence 
of conditions that would otherwise account 
for the degree of pain and dysfunction.  
4. This diagnosis is excluded by the 
existence of other conditions that would 
otherwise account for the degree of pain and 
dysfunction. 
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Table 1.2: The Harden/Bruehl Criteria, which became The Budapest Research Criteria 
with minor modifications (Harden and Bruehl, 2005) 
1. Continuing pain which is disproportionate to any inciting event. 
2. Must report at least one symptom in each of the four following categories: 
a) Sensory: report of hyperaesthesia 
b) Vasomotor: reports of temperature asymmetry and/or skin colour changes and/or skin 
colour asymmetry 
c) Sudomotor/oedema: reports of oedema and/or sweating changes and/or sweating asymmetry 
d) Motor/trophic: reports of decreased range of motion and/or motor dysfunction (weakness, 
tremor, dystonia) and/or trophic changes (hair, nail, skin) 
3. Must display at least one sign in two or more of the following categories: 
a) Sensory: evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch) 
b) Vasomotor: evidence of temperature asymmetry and/or skin colour changes and/or 
asymmetry 
c) Sudomotor/oedema: evidence of oedema and/or sweating changes and/or sweating 
asymmetry 
d) Motor/trophic: evidence of decreased range of motion and/or motor dysfunction (weakness, 
tremor, dystonia) and/or trophic changes (hair, nail, skin) 
4. There must be no other diagnosis that better explains the signs and symptoms.  
 
Table 1.3: Diagnostic signs and symptoms included in the CRPS Severity Score by 
subgroup (Harden et al., 2010) 
Self reported Symptoms  
Allodynia, Hyperpathia 
Temperature asymmetry 






Decreased active range of motion 
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Signs observed on examination 
Hyperpathia to pinprick 
Allodynia 
Temperature asymmetry by palpation 






Decreased active range of motion 
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1.2.3. Precipitating events 
Fractures, sprains and surgery of a limb are the most likely events provoking 
CRPS onset. Less commonly, injections, local infections, burns, frostbite, 
pregnancy and myocardial infarction may also lead to CRPS (Veldman et al., 
1993; Harden et al., 2010). The exact nature and severity of the trauma is 
unrelated to the combination of symptoms and their severity, with more than 
10% of patients not recalling any predisposing injury or event (de Boer et al., 
2011). Onset of CRPS type I is more often a result of trivial injuries, and the 
medical procedure or surgery in the form of treatment may make an important 
contribution to CRPS onset (Oaklander et al., 2006). Conversely, CRPS type II is 
often due (in more than 70% of documented cases in the USA) to high velocity 
missiles, or bullets, although it may also materialise after nerve injury during 
surgical procedures and improperly placed injections (Hassantash et al., 2003; 
Birch, 2009). In more than 90% of cases the nerve is only partially transected 
(Horowitz, 1984). Symptoms generally begin within a few days to a month after 
the predisposing injury in both CRPS types I and II, but 85% of type I patients 




Data on the incidence of CRPS are scarce and mostly hospital based and as such, 
the extent of the problem is largely unknown. Of the two population-based 
studies that have been performed, different results were reported: 5.5 cases per 
100,000 person years were reported in a USA-based study, while 26.2 cases per 
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100,000 person years were reported in the Netherlands (Sandroni et al., 2003; de 
Mos et al., 2007). These differences could be due to ethnicity, socioeconomic 
status, incidence of injury and screening methods for CRPS. However, as a 
general observation, European middle-aged females (~37 – 52 years) have been 
shown to be at least 3-4 times more at risk than males, although both genders at 
any age can develop CRPS (Sandroni et al., 2003; de Mos et al., 2007). 
Childhood and adolescent CRPS is extremely rare, with paediatric patients 
constituting <10% of sufferers (Wilder et al., 1992). Family members and 
siblings of young-onset patients have increased risk of developing the syndrome, 
suggesting a possible genetic predisposition or familial adoption of inappropriate 
pain-coping strategies (Shirani et al., 2010; de Rooij et al., 2009). The upper 
extremity is affected more frequently than the lower extremity (60% to 40% of 
cases), with fracture being the most prevalent cause (45%), followed by sprains 
(18%) and elective surgery (12%) (de Mos et al., 2009b). Ankle fractures are 
also observed to lead to type I more often than type II CRPS (de Rooij et al., 
2010). Many patients involved in these epidemiological studies described CRPS 
as having been associated with substantial disability, loss of quality of life, and a 
personal and economic burden (Subbarao and Stillwell, 1981).   
 
In summary, CRPS is a rare chronic pain disease of the limb that can develop 
after trauma. Its multifarious symptoms prove a challenge for diagnosis and 
complicate the understanding of its pathophysiology. However, an increase in 
expression of α-1AR in nociceptors and keratinocytes of CRPS patients has been 
described and may contribute to disease pathogenesis (Dawson et al., 2011; 
Drummond et al., 2014a; Drummond et al., 2014b). As α-1AR are thought to be 
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involved in other chronic inflammatory conditions through expression on 
immune cells, and as CRPS patients often present with persistent inflammation, 
α-1AR expression in immune cells of CRPS may provide a link between the 
malfunctioning SNS of CRPS and its persisting inflammatory response 
(Szentivanyi et al., 1979; Wahle et al., 1999; Heijnen et al., 1996; Marchand et 
al., 2005 Geertzen et al., 1998).  
 
1.3. α-1 adrenergic receptors  
While α-1 adrenergic receptors (α-1AR) may play a pathogenic role in CRPS, 
they also have many physiological roles in the maintenance of health. The α-
1AR belongs to one of three major functional classes of adrenergic receptors, 
which also include the α-2AR and the β-AR (Piascik and Perez, 2001). Through 
coupling with GTP-binding proteins, the adrenergic receptors are effector 
receptors of the SNS (Strosberg, 1993; Hein and Kobilka, 1997). Their 
physiological roles include mediation of sympathetic neurotransmission and 
control of vascular tone, as well as modulation of hepatic metabolism, cardiac 
contraction and the regulation of smooth muscle activity in the genitourinary 
system (Calzada and de Artinano, 2001; Koshimizu et al., 2003). The α-1ARs 
respond to a number of peptidergic and nonpeptidergic hormones, drugs and 
neurotransmitters, but are largely activated by the catecholamines adrenaline and 
noradrenaline (Piascik and Perez, 2001).  
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1.3.1. Subtypes 
Progression in cloning, sequencing and pharmacologic analysis has identified 
three different subclasses of α-1AR: α-1A, α-1B and α-1D  (Chen and Minneman, 
2005). These three classes are transcribed from separate genes located on 
different chromosomes (Table 1.4). Despite this, they are extremely homologous 
and mediate similar functions, respond to the same ligands and stimulate the 
same G-protein pathway (Koshimizu et al., 2003). The primary polypeptide 
structure of the three subtypes ranges from 466 to 572 amino acids that fold into 
a highly conserved structure of seven transmembrane domains (Strosberg, 1993; 
Michelotti et al., 2000). These domains create a highly specific hydrophilic 
ligand-binding pocket surrounded by a hydrophobic core. Slight changes in the 
primary sequence among these three subtypes alters the secondary structure, 
resulting in distinct changes in this ligand-binding pocket (Michelotti et al., 
2000). The effect is differing affinities for circulating ligands among subtypes 
(Docherty, 1998). The α-1AR subtypes are often co-expressed in tissues and 
cells; however, the expression-ratio appears to be species- and tissue-dependent 
(Michelotti et al., 2000; Koshimizu et al., 2003). Additionally, distinct isoforms 
of α-1A cDNA generated by alternative splicing have been identified. These 
receptors differ in length and sequence at the carboxyl terminal region of the 
gene and are named α-1A-1, α-1A-2, α-1A-3 and α-1A-4  (Huh et al., 2010).  
 
1.3.2. Physiological role  
The study and distribution of α-1AR subtypes in various organs and tissues has 
been difficult to establish due to the low abundance of mRNA and the detection 
of false positives. Little research on human α-1AR subtype function has been 
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published, but rather a variety of different functions have been described 
amongst animal species. These studies suggest that α-1A is more implicated in 
the maintenance of vascular tone and of arterial blood pressure in conscious 
animals, whereas α-1B participates more in response to exogenous agonists 
(Garcia-Sainz et al., 1999). Expression of α-1B can be modified in pathological 
situations such as cardiac hypertrophy and hypertension (Garcia-Sainz et al., 
2000). The α-1D subtype expression is scarce in comparison to α-1A and α-1B but 
is involved in cardiac function and vascular tone (Calzada and de Artinano et al., 
2001). 
 
In human studies, α-1AR exhibits a wide range of physiological roles in both 
health and disease, with particular importance in the cardiovascular system 
where it mediates cardiac smooth muscle contraction, in the skin, and also in 
nervous tissue and the liver (mediation of glycogenesis and gluconeogenesis) 
(Michelotti et al., 2000). In the vasculature, α-1A is predominantly expressed in 
arteries, whereas all three subtypes are present in veins (Rudner et al., 1999). The 
expression of α-1AR in the vasculature is modulated by age; in particular, the 
overall α-1AR expression doubles with age (>65 years compared to <55 years) 
(Michelotti et al., 2000). In the nervous system, α-1AR are expressed on 
peripheral nociceptive neurons and are responsible for sensory-sympathetic 
coupling (Dawson et al., 2011). Although there is slight variation in the function 
of each α-1AR, most cells and tissues that express α-1AR will express all three 
subtypes, thus exhibit a range of functions (Perez et al. 1994). 
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1.3.3. Ligands 
All three α-1AR subtypes have a high affinity for the biological agonists 
adrenaline and noradrenaline, the pharmacological agonist phenylephrine and the 
pharmacological antagonist prazosin (Calzada and de Artinano et al., 2001; 
Waugh et al., 1999; Marrow and Crease, 1986). Noradrenaline seemingly has a 
higher affinity than adrenaline for α-1AAR, but these two ligands share the same 
binding affinity for α-1BAR and α-1DAR.  There are select few agonists that 
show selectivity for each subtype: for example A61603, a potent 
pharmacological agonist, shows specificity for α-1AAR but not α-1BAR or α-
1DAR (Calzada and de Artinano et al., 2001; Knepper et al., 1995). However, 
subtype selectivity is seen more commonly in antagonist binding (Table 1.4).   
 
1.3.4. Cellular localisation  
Classically, G-protein binding receptors are expressed on the cell membrane 
where they are accessible to water-soluble ligands. However, reports suggest this 
may not entirely be the case for α-1AR, with studies showing major differences 
in the subcellular distribution of these receptors. Immunohistochemistry using a 
peptidergic antibody against the C-terminal region of α-1B show that α-1B is 
expressed on the surface cells (Fonseca et al., 1995). However, α-1A is expressed 
both intracellularly and on the cell surface with approximately 40% of the 
receptor expressed intracellularly (Hirasawa et al., 1997; McGrath et al., 1999). 
The α-1D receptor is very hard to detect on the cell surface, but is detectable 
intracellularly, suggesting that α-1D may be an entirely intracellular receptor 
(McGrath et al., 1999; Mackenzie et al., 2000). 
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Table 1.4. Summary of α-1AR.  (Koshmizu et al., 2003; Calzada and de Artinano, 2001)  
Nomenclature α-1A α-1B α-1D 
G- proteins Gq/11 Gq/11 Gq/11 
Potency order NA≥A A=NA A=NA 
Selective agonist A61603   










Other agonists PHE PHE PHE 
Other antagonists Prazosin Prazosin Prazosin 
Amino acid 
residues 
466 519 572 
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Gene ADRA1C ADRA1B ADRA1D 
Human 
chromosome 
8 5 20 
Cellular 
localisation 
Cell surface and 
intracellular 
Cell surface Mostly 
intracellular 
NA = noradrenaline; A = adrenaline; PHE = phenylephrine  
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1.4. Cells and regulation of the inflammatory response 
The inflammatory response aims to eliminate the initial cause of cell injury, 
remove necrotic cells and tissues damaged from the original insult and 
inflammatory process, and to initiate healing and repair (Medzhitov, 2008). As 
the majority of CRPS patients experience nerve and/or tissue trauma, an 
inflammatory response is expected to be evident at the time of injury. This 
inflammation is commonly described among the symptoms of CRPS, with limbs 
presenting as warm, swollen, and red; and being described as having a loss in 
function and increased pain. These symptoms are a result of the inflammatory 
response coordinating the delivery of leukocytes, cytokines and inflammatory 
mediators to the site of insult, regulated by a highly complex molecular system 
(Vigano et al., 2012). Under normal circumstances inflammation would resolve 
after the insult has been cleared, however this inflammation commonly persists 
in CRPS patients for reasons not fully understood. Neurogenic inflammation 
(inflammation arising from the release of neuropeptides such as substance P and 
calcitonin-gene-related-peptide) is also observed in CRPS patients, however, as it 
is beyond the scope of this project, will not be discussed in detail (Birklein et al., 
2001a; Lei et al., 2003; Schinkel et al., 2006).  The following section will 
describe in detail the cells and mediators of the inflammatory response, and 
which cell types and mediators may indicate persisting inflammation.  
 
1.4.1. Cells and mediators of the inflammatory response  
Leukocytes involved in the inflammatory response include granulocytes, 
lymphocytes and monocytes (Chaplin, 2010). Granulocytes are the most 
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abundant leukocyte and include neutrophils, basophils and eosinophils involved 
in innate immunity (Vigano et al., 2012). Lymphocytes are cells of the adaptive 
immune system and include B cells, T cells, T regulatory cells, Natural Killer 
(NK) cells and NKT cells, whereas monocytes are the blood-borne precursor for 
phagocytic tissue macrophages and some forms of specialised antigen-presenting 
cells (APC), such as dendritic cells (Chaplin, 2010). An intact immune system 
and the inflammatory response require contributions from many subsets of 
leukocytes (Medzhidov, 2008). Different leukocytes with varying functions can 
be identified by expression of differentiation proteins on their cell membrane that 
are assigned a cluster of differentiation (CD) number (Engel et al., 2015). 
Monoclonal antibodies specific for these cell surface molecules can bind to the 
CD antigen and be used for phenotyping of leukocyte subsets (Engel et al., 
2015). There are currently more than 350 defined CD antigens (Chaplin, 2010). 
One of these, the CD45 marker, is a pan-marker for all leukocytes and is a 
receptor-linked protein tyrosine-phosphatase involved in the function of all 
leukocytes (Engel et al., 2015). A variety of other CD markers can be used to 
identify subsets of CD45+ leukocytes in the peripheral blood of humans: Table 
1.5 provides a summary of the CD markers (and the cells they identify) to be 
discussed in this section, some of which were used in this study. 
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Table 1.5: CD markers for each of the different types of leukocytes 
discussed in Section 1.4.  
Cell type CD marker 
Leukocytes CD45 
Neutrophils CD6, CD11b, CD66 
Monocytes CD14, CD16 
T cells CD3 
T helper cells CD3, CD4 
T cytotoxic cells CD3, CD8  
T regulatory cells  CD3, CD4, CD25, FoxP3 
B cells CD19 
NK cells CD16, CD56  
NKT cells CD3, CD56, CD16 
 
1.4.1.1. Granulocytes 
Amongst the granulocytes, neutrophils are blood-borne non-specific phagocytic 
cells of the innate immune system of mammals that engulf microbes and release 
cytoplasmic granules (Medzhitov, 2008). They are the first cells of defence, 
migrating within ninety minutes of the initial insult. Their granules contain 
enzymes and other antibacterial substances that are used to destroy and degrade 
engulfed microbes and dead tissue (Vigano et al., 2012). Neutrophils also have 
oxygen-dependent metabolic pathways that generate toxic oxygen and nitrogen 
products that aid in the destruction of engulfed pathogens (Chaplin, 2010). 
Phenotypic surface markers used for identification of human neutrophils 
typically include CD6, an Fc receptor for immunoglobulin (Ig); CD11b, the 
protein of which is involved in cellular adhesion during phagocytosis; and CD66, 
also involved in adhesion and activation of neutrophils (Lakschevitz et al., 
2016).  
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Eosinophils and basophils produce lipid mediators and cytokines that induce 
inflammation. Eosinophils are also blood-borne granulocytes and are involved 
during allergic reactions and parasite infections. The granules of eosinophils 
contain a protein that is highly toxic to parasitic worms too large to be 
phagocytosed. Basophils bind an antibody, IgE, secreted by plasma cells through 
receptors on their cell surface. Binding to IgE triggers release of histamine and 
vasoactive agents from the basophil granules. Mast cells are tissue-resident 
basophils (Chaplin, 2010). 
 
1.4.1.2. Monocytes 
Monocytes are blood-borne mononuclear cells constituting about 3 to 8% of the 
white blood cell count (Medzhitov, 2008; Vigano et al., 2012). They migrate into 
tissues at the site of injury approximately 24 to 48 hours after the initial insult, 
and differentiate into macrophages, which are tissue-resident monocytes, and 
dendritic cells, which are specialised antigen-presenting cells (APCs) involved in 
stimulating the immune response. Monocytes and macrophages produce potent 
vasoactive mediators that promote regeneration of tissues (Chaplin, 2010). The 
circulating life span of the monocyte is three to four times higher than that of the 
granulocytes. These longer-lived phagocytes help to destroy the causative agent, 
aid in the signalling process of immunity, serve to resolve the inflammatory 
process and contribute to initiation of the healing processes. They also play an 
important role in chronic inflammation, where they can surround and wall off 
foreign material that cannot be digested (Medzhitov, 2008). Monocytes express 
CD14 and CD16 on their cell surface that can be used to identify three 
subpopulations: CD14+ CD16- (classical monocyte), CD14low CD16+ 
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(intermediate monocyte) and CD14high CD16+ (non-classical monocyte). Non-
classical monocytes display higher levels of CD14 expression than the 
intermediate CD14+ CD16+ monocyte. Classical monocytes constitute 85% of 
monocytes, whereas intermediate and non-classical monocytes make up 5% and 
10%, respectively (Wong et al., 2012). Classical monocytes are involved in 
phagocytosis whereas intermediate and non-classical monocytes are thought to 
be involved in T cell migration and proliferation. The CD14 molecule is a 
pattern-recognition receptor, aiding in the recognition of bacterial 
lipopolysaccharide (LPS), whereas CD16 is an Fc receptor, binding to the Fc 
portion of IgG antibodies (Wong et al., 2012).  
 
1.4.1.3. Lymphocytes 
As will be discussed below, there are two distinct types of lymphocytes (B cells 
and T cells) that differ in their maturation pathways and functions, but are 
morphologically similar. Additionally, Natural Killer (NK) cells and NKT cells 
are not specifically identified as lymphocytes, but share some markers and 
functional properties (Brennan et al., 2013). Most lymphocytes specifically 
recognise and respond to foreign proteins and antigens, although populations of 
self-responsive lymphocytes are generated in some individuals. Antigen 
presenting cells (APC) such as dendritic cells, and to a lesser extent, 
macrophages, “present” antigens to lymphocytes: this occurs after the APC has 
phagocytosed the antigen and processed it into fragments, which are then 
expressed on their cell surface in order to specifically activate lymphocytes 
(Chaplin, 2010). 
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1.4.1.3.1. T cells 
The T lymphocytes (or T cells) arise from bone marrow stem cells, but mature in 
the thymus, where they undergo rearrangement of genes needed for expression of 
a unique T-cell antigen receptor (Vigano et al., 2012). The T-cell receptor (TCR) 
is composed of two polypeptides that fold to form a groove that recognises 
processed antigens from antigen-presenting cells (APC) via the major 
histocompatibility complex (MHC), a cell surface protein that binds to and 
displays foreign antigens to the immune system (Masopust and Schenkel, 2013). 
The TCR is associated with other surface molecules, known as the CD3 
complex, that aid in cell signalling. The CD3 surface receptor can be used as a 
phenotypic marker for all T lymphocytes. Subpopulations of T cells can be 
divided by contributions of other cell surface markers associated with the TCR 
complex, such as CD4+ (helper) T cells and CD8+ (cytotoxic) T cell (Masopust 
and Schenkel, 2013).  
 
1.4.1.3.1.1. CD4+ Helper T cells  
The CD4+ helper T cell (TH) serves as a master regulator for the immune system. 
Activation of TH cells depends upon the recognition of antigen associated with 
MHC Class II molecules on APCs such as dendritic cells. Once activated, TH 
cells release a variety of cytokines that influence the function of all other 
inflammatory cells. Different types of cytokines released by TH cells induce 
different kinds of immune responses: for example, they can regulate antibody 
production by B cells, and activate and regulate other immune cells such as APC, 
CD8+ cytotoxic T cells, NK cells and monocytes (Baranovski et al., 2015).  
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The cytokine interleukin-2 (IL-2) is one of the first cytokines to be produced 
during activation of lymphocytes, and is necessary for the proliferation and 
function of TH cells, cytotoxic T cells and NK cells. IL-2 interacts by binding to 
IL-2 receptors on these cells (Baranovski et al., 2015). The activated TH cell can 
further differentiate into TH1 or TH2 cells based on the cytokines secreted by the 
APC during activation: the cytokine IL-12 produced by macrophages and 
dendritic cells stimulates maturation into TH1 type cells, whereas IL-4 produced 
by basophils and T cells induces differentiation towards TH2 type cells. The type 
of TH cell activated drives the type of inflammatory response produced. 
Activated TH1 cells characteristically produce the cytokines IL-2 and interferon 
(IFN)-γ, whereas TH2 cells produce IL-4 and IL-5. Some cytokines produced by 
TH2 cells (e.g. IL-4 and IL-10) inhibit macrophage activation and suppress TH1 
responses, and are considered anti-inflammatory (Noelle and Snow, 1992). In 
most immune responses, a balanced response of TH1 and TH2 is needed to 
maintain homeostasis. However, injury or exposure to different types of antigens 
(e.g. pathogens or allergens) can skew the response to one or the other subset and 
in some cases, lead to pathogenic inflammation (Masopust and Schenkel, 2013). 
The TH17 type cell is a less common type of helper T cell that produces the 
cytokines IL-17, IL-21 and IL-22 (Ouyang et al., 2008). The cytokines released 
by TH1, TH2 and TH17 cells play a number of important roles in inflammation, 
including amplification of the response through recruitment and activation of 
other inflammatory cells (Baranovski et al., 2015) 
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1.4.1.3.1.2. Regulatory T cells 
In contrast to TH cells, regulatory T cells (Treg) suppress inflammatory responses 
by inhibiting the proliferation of other potentially harmful self-reactive 
lymphocytes. They express the CD4 marker, but additionally express CD25, an 
activation marker that is the receptor for IL-2; FoxP3 and Helios, which are both 
transcription factors involved in the development and function of Treg cells 
(Takatori et al., 2015; Sakaguchi et al. 2010). There are two types of Treg cells: 
naturally occurring Treg cells that suppress immune response and, although 
express the CD4 marker, are different from T helper cells. Induced Treg cells on 
the other hand, derive from mature CD4+ T helper cells (Takatori et al., 2015). 
The regulation by these cells is antigen-specific and controlled through activation 
of the T cell receptor (TCR) by the antigen and subsequent secretion of IL-10 
and TGF-β. These cytokines inhibit the proliferation and activation of various 
lymphocytes and macrophages (Beissert et al., 2006).  
 
1.4.1.3.1.3. CD8+ Cytotoxic T cells 
Cytotoxic CD8+ T Cells are activated through binding to MHC class I/viral 
antigen complexes on the surface of any cell type after infection with virus. They 
destroy infected cells by releasing cytolytic enzymes and toxic cytokines, or 
program cell death by triggering surface molecules to initiate apoptosis (Chaplin, 
2010). Cytotoxic T cell responses are amplified by cytokines, including IFN-γ, 
produced by TH1 cells that also become activated during viral infections 
(Baranovski et al., 2015). 
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1.4.1.3.2.  B cells  
B lymphocytes (B cells) contribute to the inflammatory response by producing 
antibodies specific for target antigens. They are identified by the presence of 
CD19, a membrane immunoglobulin (Ig) that functions as the antigen receptor 
for the production and release of antibodies. During maturation in the bone 
marrow, B cell progenitors develop into mature or naïve B cells. Naïve B cells 
express membrane-bound IgD and IgM that function as receptors for antibody 
but do not secrete antibody. Mature B cells leave the bone marrow, enter the 
circulation, and migrate to the various peripheral lymphoid tissues, where the B 
cell is stimulated to respond to a specific antigen. Each stage of B cell 
development is indicated by the pattern and expression of Ig on their cell surface, 
that serve as phenotypic markers of these maturational steps (Masopust and 
Schenkel, 2013). For most antibody responses, B cells require help from TH cells 
in order to become activated and to make antibodies of different isotypes (eg. 
IgG, IgE, IgA) (Baranovski et al., 2015). 
 
1.4.1.3.3. NK cells 
Natural killer (NK) cells comprise approximately 10% to 15% of peripheral 
blood lymphocytes and do not bear T-cell receptors or cell surface 
immunoglobulins (Brennan et al., 2013). Morphologically, they are somewhat 
smaller than T and B cells and contain abundant cytoplasmic granules. NK cells 
are a part of the innate immune system, and may be the first line of defence 
against viral infections (Brennan et al., 2013). They also have the ability to 
recognise and kill tumour cells, abnormal body cells, and virally infected cells. 
Two cell surface molecules, CD16 and CD56 are widely used to identify NK 
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cells. CD16 serves as a receptor for the IgG molecule, which provides NK cells 
with the ability to lyse IgG-coated target cells (Trincheri, 1989). CD56, or the 
neural cell adhesion molecule (NCAM) is a glycoprotein involved in cellular 
adhesion (Brennan et al., 2013).  
 
1.4.1.3.4. NKT cells  
NKT cells are an additional subgroup of T cells that share NK cell properties 
(Brennan et al., 2013). They express a unique TCR, which recognises glycolipid 
antigens that are only presented by CD1d, although is still identified as CD3. 
They combine both innate and adaptive immune properties by promoting cell-
mediated immunity to tumours and infectious orgasms yet can also suppress the 
cell-mediated immunity associated with autoimmune responses and allograft 
rejection. The precise means by which these cells carry out these functions is 
unclear. NKT cells additionally express the CD56 marker (Brennan et al., 2013). 
 
1.4.2. Chronic inflammation 
A successful inflammatory response results in the elimination of the initiating 
stimulus, followed by a healing and repair phase to reestablish tissue 
homeostasis. A switch from pro-inflammatory mediators to anti-inflammatory 
mediators (eg. IL-10, TGF-β and lipoxins) mediates the resolution response, as 
well as recruitment of cells involved in healing and repair such as macrophages 
and fibroblasts. Ideally this should only span a few days; however, inflammation 
can become chronic when the inflammatory stimuli cannot be removed (Chaplin, 
2010).  
 
Chapter 1.                                                                                                              Literature Review 
 30 
Chronic inflammatory diseases are a group of clinical disorders that are 
characterised by an aberrant, non-resolving inflammatory response. Chronic 
inflammation is pathogenic and can last for many years. The acute response 
(neutrophils and activated T cells) is replaced with macrophages and 
lymphocytes (Vigano et al., 2012). It impedes injury resolution and rather than 
repairing the tissue, the persisting inflammation results in tissue destruction and 
scarring may result in organ dysfunction (Gabay, 2006). The process may be 
localised, but it often progresses to disabling diseases such as asthma, 
rheumatoid arthritis and atherosclerosis (Shacter and Weitzman, 2002). As CRPS 
patients present with persisting inflammation, it has been proposed that CRPS is 
a chronic inflammatory disease. Interestingly, as discussed further below, some 
chronic inflammatory diseases have shown α-1AR expression in leukocytes, and 
that this may play a significant role in this persisting inflammation, with little or 
no expression of α-1AR in immune cells of a healthy immune state.  
 
1.5. α-1 adrenergic receptors in inflammation  
While the most well-described influences of α-1AR are on the vasculature, 
sensory nerves and keratinocytes, there is growing evidence to show that α-1AR 
may also be differentially expressed by cells of the immune system, influencing 
inflammatory cytokine production and promoting chronic inflammation.  
Characterisation of α-1AR expression has been difficult, since many 
commercially available antibodies have been shown to be non-specific for α-
1AR, meaning that most investigations rely on RT-PCR to analyse mRNA rather 
than protein expression. However, RT-PCR is also prone to contamination and 
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lack of specificity. This could be the reason for the contradictory literature 
surrounding α-1AR expression on leukocytes, with numerous reports 
documenting an absence of α-1AR while others report expression following 
phytohemagglutinin (PHA) or lipopolysaccharide (LPS) stimulation (Casale and 
Kaliner, 1984; Kavelaars, 2002; Rouppe van der Voort et al., 2000). The 
majority of these studies were performed on peripheral blood mononuclear cell 
(PBMC) preparations, which include a mixture of several blood cell types such 
as T cells, B cells, NK cells, NKT cells and monocytes. Nevertheless, in situ 
hybridisation techniques show that PBMCs can express α-1BAR and α-1AAR, 
with α-1DAR found to a lesser extent (Tayebati et al., 2000). 
Immunocytochemistry analyses in the same study showed that the majority of 
PBMCs expressed the mature α-1BAR protein with fewer cells expressing α-
1AAR and α-1DAR.  
  
More specifically, the human monocytic cell line (THP-1) endogenously 
expresses α-1BAR and α-1DAR mRNA, whereas genomic α-1AAR expression 
can be induced following treatment with TNF-α or IL-1β (Heijnen, 2002). 
Functional α-1AR expression has also been described on primary monocytes 
isolated from human blood (Takahashi, 2005). Conversely, other studies have 
documented no detectable α-1AR mRNA from human monocytes unless they 
were cultured in the presence of glucocorticoid, dexamethasone or the β-2AR 
agonist terbutaline, which induced α-1BAR and α-1DAR mRNA (Rouppe van 
der Voort, 1999). There are suggestions that inhibition of α-1AR on monocytes 
regulates their migration (Kintscher, 2001). Other reports suggest that α-1AR 
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may be involved in complement synthesis through stimulation by adrenaline or 
noradrenaline (Lappin and Whaley, 1982). More recently, activation of α-1AR 
by phenylephrine was found to influence the modulation of cytokines such as IL-
1β, TNF-α, IL-6, IL-8 and IL-10 from monocytes stimulated with LPS, 
supporting the concept that α-1AR influences the production of and also 
responses to cytokines (Grisanti et al., 2011). 
 
Under normal conditions, T cells do not appear to express α-1AR, although some 
studies suggest that α-1AR expression may be regulated in certain lymphoid 
compartments or under certain pathological conditions. For example, 
lymphocytes from rat mesenteric lymph nodes transcriptionally express α-1AR, 
while α-1AAR and α-1DAR expression was observed in rat lymphocyte 
populations from the thymus, spleen and peripheral blood (Bao et al., 2007). 
Peripheral blood T cells do, however, show an increase in α-1AR mRNA 
activation with a T cell mitogen, suggesting a possible maturation expression 
with earlier studies demonstrating α-1AR activation to inhibit proliferative T cell 
responses (Schaunestein et al., 2000; Heilig et al., 1993). To date, specific α-
1AR expression on B cells has not been reported (Casale and Kaliner, 1984; 
Rouppe van der Voort et al., 2000; Taybati et al., 2000). 
 
In summary, it is unclear whether leukocytes typically express α-1AR in a 
healthy immune state although it appears α-1AR can be induced following 
stimulation with inflammatory mediators. Studies on cell lines that do express α-
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1AR suggest that the receptor may be involved in cell migration and complement 
synthesis, or may be indicative of maturation.  
 
1.5.1 α-1 adrenergic receptors in chronic inflammatory diseases 
Juvenile rheumatoid arthritis (JRA) is a chronic inflammatory joint disease 
associated with an increase in the level of noradrenaline, a ligand that binds to 
both β- and α- adrenergic receptors. Activation of β-2 and α-2 on macrophages 
leads to an upregulation of LPS-induced TNF-α production in vivo, promoting an 
inflammatory response (Heijnen et al., 1996). The same study found that PBMCs 
of JRA patients respond to α-1AR activation with increased production of the 
pro-inflammatory cytokine IL-6. Healthy PBMCs from this study did not 
functionally express α-1AR therefore the production of IL-6 from PBMCs in this 
case likely exacerbates disease (Heijnen et al., 1996). Further analysis revealed 
that in JRA, PBMCs expressed mRNA that encoded the α-1DAR subtype, and 
did not produce IL-8, an anti-inflammatory mediator (Rouper van der Voort et 
al., 2000). Moreover, another study suggests that it may not be a total increase in 
α-1AR that exacerbates disease but rather a shift in the ratio of β to α-1AR that 
responds to catecholamine effects in rheumatoid arthritis (Wahle et al., 1996; 
Goebel et al., 2010). Allergic asthma is another chronic inflammatory disease 
that results in an obstructed airway. Lymphocytes in lung tissue from asthmatic 
patients show the same adrenergic receptor shift from β-AR to α-1AR that is 
thought to exacerbate inflammation in chronic disease (Szentivayi et al., 1979). 
In summary, it appears that α-1AR is only expressed in immune cells following 
an inflammatory stimulus or during chronic inflammation. Therefore, whether 
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CRPS could pose as a chronic inflammatory disease is an area worth 
investigating.  
 
1.6 Inflammatory and α-1AR pathophysiology of CRPS 
1.6.1. Inflammation in CRPS 
Inflammation is a core component of the key CRPS symptoms: skin reddening, 
warmth, oedema, trophic changes, loss of function and pain. CRPS patients 
commonly experience inflammation that may persist twelve to eighteen months 
after the initial injury. As the type of cellular infiltrate during an inflammatory 
response reflects the type of insult present, examining leukocyte distributions 
relative to that of a healthy immune state may provide insight into why CRPS 
patients commonly present with persisting inflammation. The same applies for 
inflammatory mediators, as they are produced selectively by different insults, act 
on different cell types and can mediate the symptoms of pain.  
 
Monocytes and macrophages are phagocytic inflammatory cells, and along with 
dendritic cells, are involved in processing and presenting foreign proteins 
(antigens) for activation of the adaptive immune system (see Section 1.4.1.2 
above). Although total monocyte counts in CRPS patients have been shown to be 
unaltered compared to normal individuals, the ratio of the CD14+ CD16+ to 
CD14+ CD16- monocyte subgroup was raised in comparison to that of normal 
individuals (Ritz et al., 2011). Individuals with this heightened CD14+ CD16+ 
ratio also have decreased serum levels of the anti-inflammatory cytokine IL-10, 
suggesting a pro-inflammatory response (Uceyler et al., 2007). It is unclear 
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whether these immune changes are present before the onset of CRPS (in which 
case they may contribute to the onset of CRPS) or after developing CRPS (in 
which case they might play a role in its maintenance).  
 
After neuronal lesions, microglia (CNS macrophages) in the spinal cord change 
their immunophenotype, proliferate and migrate such that they exert a regulatory 
influence on synaptic transmission (Banati, 2002). In a rat model of CRPS, T 
cells infiltrate the spinal cord in response to the release of pro-inflammatory 
cytokines (possibly from microglia) with a change in the TH1/TH2 pro-
inflammatory cell ratio that results in neurogenic inflammation (Moalem et al., 
2004). A pro-inflammatory TH1 response is more likely to amplify hyperalgesia 
after a nerve lesion is repaired with an increase in the TH2 response more likely 
to prevent hyperalgesia (Cao and Deleo, 2008; Moalem et al., 2004). 
Additionally, FoxP3- knockout mice develop neuropathic pain after nerve 
lesions, suggesting that neuropathic pain can be controlled by FoxP3+ regulatory 
T cells (Austin et al., 2012). Mice without B cells and T cells have less pain 
behaviour after nerve lesions than wild-type mice, indicating the importance of 
lymphocytes for the development of pain (Costigan et al., 2009). Interestingly, as 
CRPS develops most often after fractures, fracture healing improves in animals 
without an adaptive immune system (Toben et al., 2011).  
 
Skin biopsies taken from CRPS patients show an increase in expression of the 
inflammatory mediators TNF-α and IL-6 when compared to unaffected 
individuals (Birklein and Schlereth, 2015). Blister fluid taken from the skin of 
affected limbs in CRPS patients has also been shown to have increased levels of 
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TNF-α and IL-6 compared to that of the unaffected limb (Kramer et al., 2011). 
Correspondingly, serum concentrations of soluble TNF-receptors, as well as pro-
inflammatory cytokines TNF-α, IL-1β and IL-8 were increased, whereas anti-
inflammatory cytokines IL-4, IL-10 and transforming growth factor β1 (TGF-β1) 
were decreased in CRPS patients (Schinkel et al., 2006; Uceyler et al., 2007). In 
addition to their immune cell regulatory effects, inflammatory cytokines in CRPS 
also act on peptidergic nociceptors to enhance the release of neuropeptides 
substance P and calcitonin-gene-related-peptide (CGRP) (Birklein et al., 2001a; 
Lei et al., 2003; Schinkel et al., 2006). Increased levels of these neuropeptides 
have been found in the affected skin of CRPS individuals, and are thought to 
evoke vasodilation and protein extravasation in this tissue during inflammation. 
The resulting visible symptoms (reddening, warmth and oedema) are termed 
neurogenic inflammation (Dallos et al., 2006; Weber et al., 2001; Hou et al., 
2011). Substance P induces plasma extravasation in the CRPS-affected limb, and 
may be involved in mast cell degranulation and further release of inflammatory 
mediators (Oyen et al., 1993; Weber et al., 2001).  Downstream this could 
further upregulate its own release from peptidergic nerves, potentially resulting 
in persisting inflammation (Woolf et al., 1994; Wei et al., 2009). Neurogenic 
inflammation is also observed in areas other than the affected region, suggesting 
a systemic response (Birklein and Schmelz, 2008). Additionally, the mRNA of 
metalloproteinase-9, which cleaves cytokines and neuropeptides, is upregulated 
four-fold in CRPS patients, and many microRNAs known to control the 
inflammatory process are downregulated, which may act to keep the 
inflammatory process switched on (Orlova et al., 2011). Physiologically, these 
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microRNAs travel with exosomes released from inflammatory cells in the blood 
and systemically regulate inflammation in target cells (McDonald et al., 2014). 
 
Although it is hypothesised that an increase in neuropeptides from sensory nerve 
fibres may be the cause of this persisting inflammation, how this is mediated is 
unclear. As mentioned previously, research surrounding chronic inflammatory 
diseases suggest that α-1AR are upregulated on leukocytes in an inflammatory 
state, and are functionally linked to the release of pro-inflammatory mediators. 
Whether α-1AR drives the release of mediators from leukocytes in CRPS, and 
ultimately the release of neuropeptides from sensory nerve fibres and the 
infiltration of leukocytes during inflammation, is a question that remains to be 
answered. 
 
1.6.2. Autoimmunity in CRPS 
Additional to chronic inflammatory characteristics of CRPS, there is some 
evidence that there may also be autoimmune characteristics to CRPS. 
Autoimmune disorders occur where leukocytes are unable to distinguish between 
self-antigens and foreign antigens, producing autoantibodies. Immune self-
tolerance is the ability of the immune system to recognise self-proteins from non-
self proteins, where self-reactive T and B cells are eliminated or regulated during 
maturation (Kamradt and Mitchison. 2001). As such, the breakdown of immune 
self-tolerance can result in autoimmune disorders (Davidson and Diamond, 
2001). Approximately 40% of a small cohort of CRPS patients were found to 
have autoantibodies for β-2 adrenergic receptors and muscarinic-2 receptors 
(Blaes et al., 2004; Kohr et al., 2011). These findings led to the formation of the 
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IRAM hypothesis: Injury-triggered, Regionally-restricted Autoantibody-
Mediated autoimmune disorder with minimally-destructive course, which 
describes pre-existing circulating autoantibodies becoming pathogenic after the 
individual experiences trauma (Goebel and Blaes, 2013). Goebel et al. (2010) 
proposed there may be a relative shift in the mediation of adrenergic effects from 
β to α adrenergic receptors contributing to CRPS onset, although how this occurs 
is unclear. More recently, autoantibodies specific for α-1AR were detected in 
patient sera, and it has been suggested that anti-α-1AR antibodies isolated from 
CRPS patients could enhance pain via activation of α-1AR on dorsal root 
ganglion (DRG) neurons (Dubuis et al., 2014; Reilly et al., 2016). Other signs 
indicative of an autoimmune contribution to CRPS include the improvement 
after intravenous immunoglobulin (a treatment for autoimmune inflammation) of 
α-1AR (Goebel and Blaes, 2013). Furthermore, α-1AR autoantibodies were 
found in the serum of patients who have had previous infections with chlamydia, 
parvovirus and campylobacter (Goebel and Blaes, 2013). An increased frequency 
of expression of the human leukocyte antigens (HLA) DR-2, A3 and HLA-B7, 
associated with other autoimmune diseases such as multiple sclerosis, were also 
observed in CRPS patients (Mailis and Wade, 1994; Weiner et al., 1993). These 
HLA antigens are more likely to present self-antigens to self-reactive 
lymphocytes of the immune system (Goodnow et al, 2005). However, as there 
are limited data on the role of autoimmunity in the pathogenesis of CRPS and 
with only a small number of CRPS patients expressing autoantibodies, more 
investigations into the nature of this observation need to be conducted. 
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1.6.3.  Biological susceptibility to CRPS 
While attempts to find a psychological susceptibility to CRPS are ongoing, a 
strong correlation has yet to be found (Bruehl and Carlson, 1992; Field and 
Gardner, 1997; Bruehl, 2001; Harden et al., 2003; Puchalski and Zyluk, 2005; 
Beerthuizen et al., 2011). Several observations suggest that genetic determinants 
may play a role in the predisposition to develop CRPS. In particular, the 
distribution of polymorphisms in various cytokine, neurotransmitter and 
adrenergic receptor genes has been examined. A significant association with an 
α-1AAR polymorphism has been detected (Herlyn et al., 2010). However, the 
relevance of this finding is unclear since the polymorphic variant does not differ 
pharmacologically (Heryln et al., 2010). Particular HLA genotypes show a clear 
pattern of inheritance among CRPS patients, with the HLA-DQ1 and HLA-DR2 
alleles significantly more frequent in CRPS I patients (Mailis and Wade, 1994; 
Kemler et al., 1999). Moreover, a polymorphism in the TNF-α promoter gene 
has been associated with the occurrence of the disease, with homozygosity for 
this allele increasing the risk of having more than one extremity involved 
(Vaneker et al., 2002).  
 
1.6.4. α-1 adrenergic receptors in CRPS 
Additional to evidence suggesting α-1AR is a target for autoantibodies in CRPS 
and/or subject to genetic polymorphism leading to disease onset, atypical α-1AR 
expression has been described in CRPS throughout the vasculature, nervous 
system and within the skin. Skin biopsies taken from CRPS type I individuals 
also show an increase in expression of α-1AR on keratinocytes and cutaneous 
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nociceptors (Drummond et al., 1996; Drummond et al., 2014a; Drummond et al., 
2014b). Previous studies have suggested that decreased noradrenaline levels 
and/or pro-inflammatory mediator influence may account for this increased α1-
AR expression (Drummond et al., 1991; Kurvers et al., 1995; Heijnen et al., 
2002). As shown in Figure 1.3, a decrease in noradrenaline levels in the blood 
may result in a compensatory increase in α-1AR expression in an attempt to 
increase ligand-receptor binding affinity. Whilst this initially has no apparent 
effect, when noradrenaline levels finally return to normal, this increase in ligand-
receptor binding affinity results in supersensitivity to circulating noradrenaline 
and catecholamines (Wasner et al., 2001; Wasner et al., 1999). Clinically, the 
supersensitivity to noradrenaline results in vasoconstriction, causing decreased 
blood flow and a cold limb develops. Decreased catecholamine levels in CRPS 
patients support this model, with hyperalgesia increasing when patients were 
exposed to the α-1AR agonist noradrenaline or phenylephrine (Wasner et al., 
1999; Harden et al., 1994). Unfortunately, treating patients with sympathetic 
blockade and blocking the effect of noradrenaline on adrenergic receptors is 
unsatisfactory as an all-round treatment for CRPS as only 30% of patients are 
relieved of their symptoms (Cepeda et al., 2002; van Eijs et al., 2012).   
 
 
Nerve fibres surviving after injury become more sensitive to the α-1AR agonists 
phenylephrine and noradrenaline (Ali et al., 2000; Torebjork et al., 1995). 
Blocking α-1AR with a potent antagonist (prazosin) in human patients inhibits 
dynamic allodynia and hyperalgesia in the CRPS-affected limb as well as axon-
reflex vasodilation induced by the iontophoresis of phenylephrine in healthy 
controls (Drummond et al., 2016). Continual noradrenaline released by the 
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sympathetic nerves might activate or sensitise the affected afferent neurons 
(Gibbs et al., 2008). This sympathetic coupling forms the basis of the 
sympathetically maintained pain theory, and is supported by observations of 
patients reporting pain relief after sympathetic blockade (Marinus et al., 2011).  
 
 Figure 1.3: α-1AR involvement in CRPS. An impaired sympathetic nervous system produces a decreased 
level of noradrenaline. A compensatory increase of α-1AR in the vasculature results in supersensitivity to 
circulating catecholamines. When the SNS function finally restores, this supersentivity clinically results in 
vasoconstriction of blood vessels and a cold limb develops.  
 
In summary, the role of α1-AR in CRPS pathogenesis is potentially extensive, 
with influences among vascular tone and decreased blood flow, as well as on 
keratinocytes and nerve fibres at the site of injury. With a small but significant 
number of CRPS patients reporting pain relief when α-1AR is antagonistically 
blocked, the evidence of sensitisation of nociceptors by cytokines, and evidence 
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that α-1AR is expressed in the immune system especially in chronic 
inflammatory diseases, the pathogenic role of α-1AR may not solely be confined 
to the vasculature, skin and nerve cells, but may also extend to the immune 
system and the inflammatory responses.  
 
1.7. Summary  
Complex regional pain syndrome is a debilitating disorder characterised by 
chronic causalgic pain, inflammation and autonomic disturbances in response to 
injury (Geertzen et al., 1998; Veldman et al., 1993; Harden et al., 201). Its 
multifarious symptoms prove a challenge for diagnosis, thus diagnosis relies on 
clinical evaluation and exclusion by the IASP criteria (Harden and Bruehl, 2005). 
These criteria can be assembled into a severity score, which is a quantitative 
index of the number of symptoms the patient experiences, that allows clinicians 
and researchers to more accurately understand the extent of disease (Harden et 
al., 2010).  
 
The majority of CRPS patients experience persisting inflammation localised to 
the site of injury (Borchers and Gerschwin, 2014; Birklein and Schlereth, 2015). 
Assessing the types of cellular infiltrate can contribute to an understanding of 
why this inflammation persists. Previous studies show an increase in the CD14+ 
CD16+ monocyte ratio that likely resembles a pro-inflammatory response (Ritz et 
al., 2011). Additionally, an increase in production of pro-inflammatory cytokines 
was also shown in skin biopsies and serum levels of CRPS patients when 
compared to that of a non-CRPS healthy control, as well as a decrease of anti-
inflammatory cytokines in patient sera (Kramer et al., 2011; Schinkel et al., 
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2006; Uceuler et al., 2007). Increased levels of pro-inflammatory cytokines 
likely stimulate sensory nerve fibres to produce neuropeptides, which in turn 
evoke vasodilation, protein extravasation and mast cell degranulation to release 
further inflammatory mediators, all contributing to persisting inflammation 
(Birklein et al., 2001; Lei et al., 2003; Schinkel et al., 2006; Guo et al., 2012).   
 
The α-1AR are receptors of the SNS expressed throughout the nervous, vascular 
and hepatic systems (Hague et al., 2003; Koshimizu et al., 2003). They respond 
mainly to the catecholamines noradrenaline and adrenaline, however the three α-
1AR subtypes (α-1A, α-1B and α-1D) differ in their affinities to other circulating 
ligands, and particularly for their antagonists (Piascik and Perez, 2001; Marrow 
and Crease, 1986; Michelotti et al., 2000; Docherty, 1998). Increased expression 
of α-1AR on sensory nerve fibres, keratinocytes and smooth muscle cells in the 
vasculature of CRPS patients indicates that its atypical expression may 
contribute to disease pathogenesis (Kurvers et al., 1995; Arnold et al., 1993; 
Drummond et al., 1996; Drummond et al., 2014a; Drummond et al., 2014b). 
Other studies also show α1-AR may be a target for autoantibodies during the 
breakdown of immunological tolerance following injury, with an association of 
polymorphism within the α-1AAR subtype, and also certain HLA genotypes, also 
suggesting a genetic susceptibility (Dubuis et al., 2014; Heryln et al., 2010). 
With contradictory reports of their expression throughout the immune system in 
health, confirmed expression in chronic inflammatory diseases such as JRA and 
asthma suggest their role in the immune system may be confined to a pathologic 
state (Heijnen et al., 1996; Rouper van der Voort et al., 2000; Wahle et al., 2006; 
Goebel et al., 2010).  
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2. Hypothesis and Aims 
As CRPS patients commonly present with persisting inflammation and are 
already known to overexpress α-1AR in nociceptors and keratinocytes, this study 
investigated whether α-1AR is also abnormally expressed in the immune system 
of CRPS patients, by analysing α-1AR expression by leukocytes isolated from 
the peripheral blood. The leukocyte profile in CRPS and non-CRPS individuals 
was also assessed, as a shift in distribution or numbers of leukocytes could 
provide further evidence for a role of inflammation in CRPS.  
 
2.1. Project hypothesis 
The basic hypothesis for this project is that CRPS patients will have altered α-
1AR subset expression in their PBMCs, and show an altered or more 
inflammatory PBMC subset distribution, compared to non-CRPS healthy 
individuals. 
 
2.2. Project aims 
To determine a potential link between α-1AR expression on leukocytes and the 
development of CRPS, the overall aim of this project was to examine the 
expression of α-1AR on peripheral blood mononuclear cells (PBMC) of patients 
with CRPS, and to examine the distribution of sub-populations of PBMCs in 
these patients.  
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The specific aims of this project were:  
1. To determine the expression of α-1AAR, α-1BAR and α-1DAR mRNA 
using quantitative polymerase chain reaction (qPCR) in total PBMCs 
from a range of healthy individuals. 
2. To compare the expression levels of α-1AAR, α-1BAR and α-1DAR 
mRNA in total PBMCs from healthy individuals with those of patients 
diagnosed with CRPS. 
3. To compare the distribution of PBMC subsets in healthy individuals with 
those of CRPS patients using multi-parameter flow cytometry.  
 
Chapter 3.                                                                                                      Methods and Materials 
 46 
3. Methods and Materials 
3.1. Participants 
Subject participation was entirely voluntary and was approved by the Murdoch 
University Human Research Ethics Committee (Approval 2014 27). 
 
3.1.1. CRPS patients 
Study participants included twenty CRPS patients who presented for clinical 
evaluation and treatment at the practice of Dr. Phil Finch (MB BS, DRCOG, 
FFPMANZCA) and/or the Centre for Research on Chronic Pain and 
Inflammatory Diseases at Murdoch University. All CRPS patients met published 
International Association for the Study of Pain (IASP) diagnostic criteria for the 
disorder (Harden and Bruehl, 2005). Patients were allocated a CRPS severity 
score (CSS) based on their clinical evaluation (Harden et al., 2010). The CSS 
was determined by appointing a score of 1 for the presence or a score of 0 for the 
absence for the symptoms listed in Table 3.1, using the clinical evaluation sheet 
and questionnaire documented in Appendix 1.   
 
3.1.2. Healthy controls 
A group of twenty non-CRPS healthy volunteers from around the Perth 
metropolitan region were age- and sex-matched to the CRPS patients. Controls 
were considered healthy where there was no previous history of chronic pain 
disorders, chronic inflammatory disorders and/or autoimmune disorders, the 
participant was not currently taking anti-inflammatory medication, antibiotics, 
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corticosteroids and/or immunosuppressive medication, had not had any 
vaccinations within the week prior to blood collection and were not having any 
flu-like symptoms or feeling ill on the day of blood collection. 
 
Table 3.1: CRPS severity score (CSS) symptoms. Patients allocated a score of 1 for every 
symptom listed on this table. Appendix 1 documents the questionnaire and clinical examination 
sheet used to determine these symptoms.  
Self reported symptoms 
(Recorded by questionnaire) 
Signs observed by examination 
(Recorded by clinical examination) 
1. Allodynia 
-Patient asked if increased pain to light and 
heavy stimulus 
8. Allodynia  
-Brush device, pressure/pain threshold 
2. Temperature asymmetry 
-Patient asked if affected limb feels colder or 
warmer than unaffected 
9. Temperature asymmetry 
-Temperature gauge 
3. Skin colour asymmetry 
-Patient’s observation 
10. Skin colour asymmetry 
-Examiner’s observation 
4. Asymmetric oedema 
-Patient’s observation 
11. Sweating asymmetry 
-Examiner’s observation 
5. Trophic changes 
-Patient’s observation 
12. Asymmetric oedema 
-Examiner’s observation 
6. Motor changes 
-Patient asked if they experience dystonia, 
tremor or weakness in limb 
13. Trophic changes  
-Examiner’s observation 
7. Decreased range of motion 
-In joints/ soft tissue/muscle 
 
Total score: 13 
 
3.2. Blood collection 
Subjects provided written informed consent before venipuncture. A sample of 12 
mL of venous blood was obtained by a 21-gauge needle into lithium heparin 
anticoagulant vacutainers by a licensed phlebotomist either at Dr. Finch’s clinic 
or at Murdoch University in the School of Psychology and Exercise Science or 
School of Veterinary and Life Sciences. Blood was taken from the median 
cubital vein of the non-symptomatic limb of CRPS patients and the volunteers’ 
non-dominant limb.  Lithium heparin was chosen as the optimal anticoagulant 
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for both flow cytometry and RNA extraction. Blood was obtained in a sterile 
manner and subjects were rested and observed for a period of ten minutes after 
venipuncture. The blood sample was stored at room temperature until processing.   
 
3.3. PBMC isolation from whole blood 
Blood samples were stored for a maximum of 2 hours before processing. Whole 
blood was diluted 1:1 with phosphate-buffered saline (PBS) (Sigma-Aldrich, 
Castle Hill, NSW, Australia) and carefully layered, to prevent mixing of 
solutions, on ficoll separation solution Lymphoprep™(STEMCELL 
Technologies Pty Ltd, Tullamarine, VIC, Australia) at a 3:1 ratio. The 
Lymphoprep™/diluted blood solution was centrifuged at 800 x g for 20 minutes 
at 21 °C with no break. Centrifugation produced a layered media based on the 
density of blood components as demonstrated in Figure 3.1. The buffy coat was 
extracted from the separated solution with a glass Pasteur pipette and transferred 
to a new Falcon™tube. The extracted buffy coat was diluted 10:1 with PBS and 
centrifuged for 10 minutes at 250 x g at room temperature with a high break to 
wash and pellet the cells. After centrifugation, the supernatant was discarded and 
the cells were resuspended in 1 mL PBS for cell counting by haemocytometer. 
 
Figure 3.1: Separating diluted blood with Ficoll solution produces a density gradient of the 
components of blood. Plasma is the least dense and rises to the surface of the media, erythrocytes are the 
most dense and sink to the bottom. PBMCs form a layer just under plasma and were separated from the 
media using a glass Pasteur pipette.  
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3.3.1. PBMC cell counts and viability analysis 
To count viable cells, 10 µL of resuspended PBMCs were diluted with 10 µL of 
0.4% Trypan Blue (Sigma-Aldrich, Castle Hill, NSW, Australia) solution and 10 
µL of the PBMC/Trypan Blue solution was loaded into a haemocytometer 
chamber and examined immediately at 40 x magnification under a light 
microscope. Viable (live) cells excluded the Trypan Blue dye and appeared clear, 
whereas dead cells accumulated Trypan Blue in the cytoplasm and appeared blue 
under the microscope. An average of total cell count (live + dead) and live count 
was taken from the counts of the top left corner of the haemocytometer grid and 
the bottom right corner (see Figure 3.2) and multiplied x 104 to account for the 
initial dilution factor and again x 2 for the Trypan Blue dilution factor. Cell 
viability was determined by live cell count divided by total cell count.  
 
 
Figure 3.2: Method of counting cells using haemocytometer. Cells loaded onto the haemocytometer 
disperse throughout the grid. An average of the total count of all cells (live and dead) counted from the top 
left and bottom right grids was taken, as well as the total live cell count (live only). The counts were then 
multiplied by 104 and 2. Viability was determined by dividing live cell count by total cell count.   
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3.3.2. PBMC lysis for RNA extraction and qPCR  
Based on the total live cell count, one million cells were removed and 
centrifuged at 250 x g at room temperature for 10 minutes, resuspended and 
lysed in 350µL of Isolate II RNA Mini Kit Lysis Buffer RLY™ (Bioline Pty Ltd, 
Alexandria, NSW, Australia; see Appendix 2) + 3.5 µL 2-Mercaptoethanol 
(βME). Lysed cells were vigorously vortexed and stored in Lysis Buffer RLY at 
-80°C for later RNA extraction. 
 
3.3.3. PBMC cryopreservation for flow cytometry analysis 
After cell removal for RNA extraction, the remaining live PBMCs were 
centrifuged at 250 x g at room temperature for 10 minutes and resuspended in 
freezing medium at a concentration of 1 x 106 live cells/ mL for 
cryopreservation. Freezing medium contained 10:1 heat inactivated Fetal Bovine 
Serum (FBS) (Serana, Bunbury, WA, Australia): dimethyl sulphoxide (DMSO) 
(Sigma-Aldrich, Castle Hill, NSW, Australia). One mL aliquots (1 x 106 
PBMCs) were added to 1.5 mL cryovials tubes, which were then stored 
overnight in Nalgene® Mr. Frosty™ (Thermo Fisher Scientific Pty Ltd, 
Scoresby, VIC, Australia) that contained 100% isopropyl alcohol at room 
temperature, at -80°C. The following day the vials were removed from 
Nalgene® Mr. Frosty™ and stored in liquid nitrogen.  
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3.4. α-1AR analysis of PBMCs by qPCR 
3.4.1. RNA extraction and analysis 
RNA was extracted from PBMCs following the Isolate II RNA Mini Kit protocol 
(Bioline Pty Ltd, Alexandria, NSW, Australia) (Figure 3.3). Reagents used in 
this protocol are listed in Appendix 2. Lysed cells that had been stored at -80oC 
in Lysis Buffer RLY (see Section 2.3.2) were thawed and filtered through an 
ISOLATE II collection tube filter to clear any cellular debris before the RNA 
binding conditions of the lysate were adjusted with 350 µL 70% ethanol. RNA 
was bound to a silica membrane by centrifugation at 11,000 x g for 30 seconds 
and desalted with membrane desalting buffer (MEM). The RNA was incubated 
with 10% DNase 90% DNase reaction buffer I for fifteen minutes at room 
temperature to digest genomic DNA, then washed once with wash buffer RW1 
and twice with wash buffer RW2 by centrifugation before elution in 40 µL of 
RNase/DNase free water (Figure 2.3).  
 
Eluted RNA was stored on ice until analysis by spectrophotometer NanoDrop™ 
2000 (Thermo Fisher Scientific Pty Ltd, Scoresby, VIC, Australia) to measure 
nucleic acid concentration and blanked with 1 µL of RNase free water before, 
after and in-between samples. Two x 1 µL volumes of each sample were 
measured, recording the RNA concentration (ng/µL), A260/A280 and 
A260/A230 ratios, taking an average. If the difference between the samples were 
greater than 10%, a third sample was measured. The A260/A280 ratio is used to 
determine protein contamination of a nucleic acid sample whereas the 
A260/A230 ratio indicates the presence of organic contaminants such as 
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chaotropic salts. Pure RNA should have an A260/A280 ratio around 2.1 with an 
A260/A230 ratio above 1.8.  
 
After RNA extraction and analysis, samples were stored in -80°C until cDNA 
synthesis.    
 
 
Figure 3.3: RNA extraction protocol following Bioline Isolate II RNA mini kit protocol.  
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3.4.2. cDNA synthesis  
As a first step for PCR analysis, complementary DNA (cDNA) was synthesised 
from extracted RNA using the SensiFAST cDNA Synthesis Kit™(Bioline Pty 
Ltd, Alexandria, NSW, Australia). The kit contains 5 x concentrated TransAmp 
Buffer and Reverse Transcriptase. The 5 x TransAmp Buffer contains a series of 
anchored oligo dT that anneal to the poly-A tail found on the 3’ end of 
eukaryotic mRNA and random hexamer primers to cover other segments of the 
RNA 3’ to 5’, randomly (see Appendix 3). This gives a cDNA pool 
representative of the transcriptome. The TransAmp Buffer also contains reverse 
transcription enhancers to assist the reverse transcriptase by reducing complex 
RNA secondary structure. The reactions were prepared to produce a total volume 
of 20 µL per cDNA sample (Table 3.2).  
  
Table 3.2: cDNA synthesis preparation. 
Total RNA  nµL 
5 x TransAmp Buffer 4 µL 
Reverse Transcriptase 1 µL 
DNase/RNase free water Up to 20 µL 
Total = 20 µL 
 
 
The amount of RNA used for cDNA synthesis was the same across all samples 
and was determined by the smallest concentration of RNA obtained from 15 µL 
(Total volume =20 - 4 µL Buffer - 1 µL RT) of the 40 (20 CRPS and 20 control) 
lysed PBMC subject samples using the following formula:   
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Where sample A refers to the smallest RNA concentration obtained from all 
CRPS and healthy participants and sample n refers to the volume of RNA in 
question. For example, if the smallest concentration of RNA extracted was 20 
ng/ µL (i.e. sample A) and the concentration from sample n was 50 ng/ µL: 
 
 
Then the volume of RNA needed from sample n for cDNA synthesis would be 6 
µL. The remaining volume for cDNA preparation was topped up to 20 µL with 
RNase free/ DNase free water (i.e. 9 µL).  
 
RNA extractions stored at -80 °C were thawed on ice. To ensure there was no 
DNA contamination from the RNA extractions, a negative reverse transcriptase 
control was included (- RT control). Where there was no reverse transcriptase in 
this sample, an extra 1 µL of water was added. The samples were run through the 
program showed in Table 3.3 through a T100™ Thermocycler (Bio-Rad, 
Gladesville, NSW, Australia). When finished, the 20 µL cDNA samples were 
stored at -20 °C for later qPCR analysis.  
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Table 3.3: Thermocycler program for cDNA synthesis.  
Temperature Time Comments 
25 °C 10 minutes Primer annealing 
42 °C 15 minutes Reverse Transcription 
85 °C 5 minutes Inactivation 
4 °C Infinite Hold  
 
 
3.4.3. qPCR analysis of α1-AR in PBMCs 
Quantitative-PCR (qPCR) analysis followed the SensiFAST™Probe No-ROX 
(Bioline Pty Ltd, Alexandria, NSW, Australia) kit protocol. The kit contained 2 x 
Sensifast No-ROX master mix that included dNTPs, stabilisers and enhancers. 
External pre-made TaqMan® Gene Expression Assays were purchased from In 
Vitro Life Technologies (Noble Park North, VIC, Australia) for α-1AAR (cat 
#Hs00169124_m1), α-1BAR (cat #Hs00171263_m1) α-1DAR (cat 
#Hs00169865_m1) and UBE2D2 (Hs00366152_m1). UBE2D2 was used as an 
internal control and house-keeping gene for each of the samples tested. It 
encodes the gene for the ubiquitin-conjugating enzyme E2 D2 that functions in 
the ubiquitination of the tumour-suppressor protein p53 and is widely used as a 
house-keeping gene for human PBMC qPCR analysis (Hollams et al., 2009). In 
Vitro TaqMan assays contain a probe, forward and reverse primers at 20 x 
concentration, thus for a 20 µL sample, only 1 µL of assay was used. cDNA 
samples were diluted 1:10 with RNase/DNase free water. The qPCR samples 
were set up in duplicates as shown in Table 3.4 and run Rotor-Gene® Q (Qiagen, 
Chaldstone Centre, VIC, Australia) with the program shown in Table 3.5. 
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Table 3.4: qPCR reaction preparation.  
2 x Sensifast No-ROX mix 10 µL 
20 x Taqman Primer 1 µL 
Diluted cDNA template  4 µL 




Table 3.5: qPCR program for Rotor-Gene Q.  
Cycles Temperature Time Notes 
1 95 °C 2 minutes Polymerase activation 
40 95 °C 10 seconds Denaturation 
 60 °C 30 seconds Annealing/extension 
(acquired at end of step) 
 
3.4.4. Optimisation of TaqMan Assays  
To ensure that TaqMan assays were functional, the fluorescent signal was 
measured from confirmed positive and negative controls for each of the assays.  
 
3.4.4.1. α-1A AR optimisation using the CHO-α-1AAR cell line. 
The CHO-α-1AAR cell line is an epithelial cell line derived from Chinese 
Hamster Ovary, transfected with the human α-1AAR gene. These cells express 
high levels of human α-1AAR protein on their cell surface (a gift from Prof. 
Roger Summer at Monash University). Non-transfected CHO cells were used as 
a negative control, although non-transfected CHO cells are known to express low 
levels of endogenous hamster α-1AAR. 
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3.4.4.2. α-1BAR and α-1DAR optimisation in HaCat cells 
The HaCat cell line (DKFZ-German Cancer Research Centre) is a spontaneously 
immortalised human keratinocyte cell line that expresses the human α-1BAR and 
α-1DAR subtypes after exposure to TNF alpha and were kindly provided by 
Linda Wijaya. Non-template controls were used as the negative control. 
 
3.4.4.3. UBE2D2 optimisation in PBMCs 
UBE2D2 is widely used as a house-keeping gene particularly in PBMCs 
(Hollams et al., 2009). cDNA converted from RNA isolated from PBMCs from 
one CRPS patient and one healthy control were used in optimisation of UBE2D2. 
A non-template control was used as a negative control.  
 
3.4.5. qPCR and α-1AR analysis 
α-1AR expression was determined by cycle threshold (Ct) values that represent 
the number of cycles needed for a fluorescent signal to cross a threshold. This 
was produced using Rotor-Gene® Q software. Rotor-Gene® Q software output 
were analysed by GraphPad prism (version 7.0a).  
 
3.5. Analysis of PBMC cellular composition by flow cytometry  
3.5.1. Thawing of cryopreserved PBMC  
Prior to analysis, at least 1 x 106 cells (~1 vial) were thawed from liquid nitrogen 
by immediate exposure to a 37°C water bath. Once liquefied, they were 
immediately diluted 1:10 in 9:1 PBS:FBS fluorescence activated cell sorter 
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(FACS) buffer. Diluted PBMCs were then centrifuged for 10 minutes at 250 x g 
at room temperature to pellet the cells. The supernatant was discarded and cells 
were resuspended in 1 mL FACS buffer. To determine cell viability, cells were 
counted using Trypan Blue as described in Section 3.3.1.  
 
3.5.2. Identification of PBMC subsets using fluorochrome conjugated 
monoclonal antibodies and flow cytometry 
Identification of PBMC subsets was based on the ability of specific monoclonal 
antibodies, conjugated to specific fluorophores, to bind to unique combinations 
of cell surface proteins expressed by each subpopulation of PBMCs. Activation 
of the fluorophores by appropriate lasers of different wavelengths (blue, red or 
violet) will cause them to emit fluorescence signals of different wavelengths, 
which can then be measured and converted to digital signals by light detectors 
within a flow cytometer. The flow cytometer used for this study was able to 
assess a combination of 10 different fluorophores per sample. PBMC subsets 
were analysed by staining cells with a cocktail of 8 monoclonal antibodies linked 
to different fluorophores contained in the Beckman Coulter Duraclone IM 
Phenotyping Basic Tube™(Lane Cove, NSW, Australia), as well as the addition 
of BD Horizon™BV421 Mouse Anti-Human CD25 (North Ryde, NSW, 
Australia) and viability dye 7-Amino-Actinomycin D (7AAD) (Beckman 
Coulter, Lane Cove, NSW, Australia). A summary of the fluorochromes and 
their markers is shown in Table 3.6. 




Table 3.6: Monoclonal antibodies from Duraclone panel and their associated fluorochrome.  
Laser Fluorochrome Marker Excitation Emission peak 
Blue FITC CD16 488 nm 525 nm 
Blue PE CD56 488 nm 575 nm 
Blue ECD CD19 488 nm 613 nm 
Blue 7AAD Viability 488 nm 650 nm 
Blue PE-Cy7 CD14 488 nm 720 nm 
Red APC CD4 633 nm 660 nm 
Red A700 CD8 633 nm 720 nm 
Red APC-A750 CD3 633 nm 783 nm 
Violet BV421 CD25 405 nm 421 nm 
Violet Krome Orange CD45 405 nm 528 nm 
 
3.5.3. Monoclonal antibody staining of PBMCs 
Each Duraclone tube contained a panel of 8 fluorochrome-conjugated 
monoclonal antibodies (CD3, CD4, CD8, CD14, CD16, CD19, CD45, CD56) 
that had been previously titrated and optimised by Beckman Coulter™. In 
addition, 5 µL of CD25-BV421 was added to the antibody cocktail prior to the 
addition of PBMCs. A single Duraclone + CD25 tube was used for each sample. 
Cells stained with single antibodies were also used for compensation setting and 
cytometer setup. For analysis, 100,000 live cells (~120 µL to 150 µL cells) were 
added to each of the Duraclone + CD25 tubes, then vortexed and incubated in the 
dark for 15 minutes. Samples were then washed with 1 mL FACS buffer and 
centrifuged at 300 x g for 5 minutes at 6 °C. The supernatant was discarded and 
labelled PBMCs were then resuspended in 500 µL FACS buffer. At this point, 10 
µL of the 7AAD viability dye was added to the resuspended sample.  
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3.5.4. Single antibody staining for flow cytometer compensation settings 
For each of the antibodies in the Duraclone panel, a single stain control tube was 
provided as part of the Duraclone kit, with 5 µl of each added to individual clean 
FACS tubes. For the CD25-BV421 single stain control, 5 µL was added to a 
clean FACS tube. For single staining, 100,000 live PBMCs were added to each 
of the tubes, vortexed and incubated in the dark for 15 minutes at room 
temperature. Samples were washed with 1 mL FACS buffer and centrifuged at 
300 x g for 5 minutes at 6 °C. The supernatant was discarded and single-stained 
PBMCs were resuspended in 500 µL FACS buffer.  
 
The 7AAD single stain tube involved 100,000 live cells incubated in a clean 
FACS tube at -20°C for 30 minutes to induce apoptosis. 10 µL 7AAD was then 
added to the sample.  
 
3.5.5. Analysis of PBMC subsets by flow cytometry 
Resuspended PBMC (either labelled with the full Duraclone panel+CD25, or as 
single stain controls) were collected and analysed using a Beckman Coulter 
Gallios™ 10-colour flow cytometer equipped with a blue, red and violet laser, 
together with Kaluza™ acquisition software. Single stain samples were run first 
to adjust instrument and compensation settings prior to running cells stained with 
the full panel of markers. Cell surface fluorescence colour and mean 
fluorescence intensity (MFI) determine the type (i.e. which CD marker) and the 
amount (i.e. strength of expression) of antibody bound to the cell surface 
respectively. Percentage expression and MFI data was exported from the Kaluza 
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analysis software into Microsoft Excel and GraphPad Prism software for further 
analysis.  
 
3.6. Statistics  
Normality of the data was determined by a D’Agostino & Pearson test. For 
parametric values, statistical significance between groups was determined by 
unpaired t-test or analysis of variance (ANOVA). Correlation between variables 
was determined using Pearson’s correlation coefficient. For non-parametric 
values, statistical significance between groups was determined using a Mann-
Whitney test. Two-tailed calculations were considered significant where p < 
0.05. One-tailed calculations were used where there were directional hypotheses 
from previous studies and were considered significant where p < 0.05. 
Calculations were performed with the aid of statistical analysis software (Graph 
Pad Prism version 7.0a).  
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4. Results 
4.1. Participants  
4.1.1. CRPS patients 
Of the twenty CRPS patients studied in this project, 75% were female and 25% 
were male (Table 4.1). At the time of blood extraction, the average age was 51 
years with the youngest aging 24 years and the oldest 70 years (standard 
deviation: 10.817 years; median age: 52). D’Agostino and Pearson tests of age 
and sex show this sample group was derived from a normal distribution. Surgery 
was the most common predisposing event (30%), followed by sprain (25%), 
fracture (20%), tendon damage (10%), hyperextension injury (5%), dislocation 
(5%) and crush injury (5%). The right side was affected in half of the cases, 
whereas upper extremity injuries were more common than the lower extremity 
(65% to 35%) (Table 4.1).  
 
CRPS participants could not be categorised into CRPS type I or II due to several 
participants having inclusive nerve injury evaluation prior to this study. Patients 
were allocated a CRPS severity score (CSS) based on the number of symptoms 
they experienced (Appendix 1), following the International Association for the 
Study of Pain (IASP) diagnostic criteria (Harden and Bruehl, 2005; Harden et al., 
2010). Symptoms were assessed, on a scale of 1 – 13, with the most severe 
CRPS case in this study scoring 12 and the least severe scoring 5. The duration 
of CRPS among patients was also documented, which ranged from as chronic as 
21 years to as acute as 4 months.  
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4.1.2. Correlation analysis of variables 
A D’Agostino and Pearson test showed the duration of disease, degree of 
severity and the age of CRPS patients were derived from a normal distribution 
and were assessed for correlation. This study showed no correlation between the 
duration of disease with the degree of severity (p = 0.100), the degree of severity 
and the age of the participant (p = 0.207) or the age of the participant with the 
duration of disease (p = 0.447).  
 
4.1.3. Healthy controls  
Healthy controls were age- and sex-matched with CRPS participants as 
summarised in Table 4.1. Age differences between CRPS patients and their 
matched healthy controls were no greater than five years, with the average age 
being 51.2 years (standard deviation: 11.674; median: 51.5) and a range of 21 to 
74 years. The age of the healthy control group was derived from a normal 
distribution.  





Table 4.1: Summary of patient demographics. Includes age and sex of patient, corresponding to the type of 
injury, extremity affected, severity score (CSS) and duration of disease. Patients were age-sex matched with 
healthy controls.  
Patient 
ID 









   Side Upper/
Lower 
   ID Age  Sex 
P1 50 F R U Surgery 5 3.5 C1 47 F 
P2 63 M L L Fracture 7 16.5 C2 66 M 
P3 62 F L U Surgery  9 6 C3 61 F 
P4 59 F R U Sprain 8 7 C4 55 F 
P5 53 F R U Fracture 7 2 C5 52 F 
P6 61 F L L Sprain 9 20 C6 61 F 
P7* 49 F L U Sprain * 19 C7 45 F 
P8 42 F R L Sprain 11 7 C8 46 F 
P9 60 F L U Surgery 7 9 C9 56 F 
P10 33 F R L Surgery 9 6 C10 33 F 
P11 52 M L U Crush 
injury 
9 21 C11 52 M 
P12 45 F L U Hyper-
extension 
9 0.3 C12 47 F 
P13 70 M L U Dislocation 5 3.5 C13 74 M 
P14 53 F L L Sprain 9 8 C14 54 F 
P15 24 F R U Tendon 
damage 
8 6 C15 21 F 
P16 42 M R L Surgery 10 17 C16 42 M 
P17 52 M R U Fracture 12 0.3 C17 50 M 
P18 60 F R L Surgery 10 19 C18 64 F 
P19 48 F L U Fracture 9 2 C19 47 F 
P20 51 F R U Tendon 
damage 
10 2 C20 51 F 
*Due to unforeseen circumstances, a CSS for this patient was not obtained. 
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4.2. PBMC isolation from whole blood 
4.2.1. Cellular recovery  
The cellular recovery (cells/ mL of whole blood) of total PBMCs isolated from 
the blood of CRPS and control participants is shown in Figure 4.1. As this 
sample group was derived from a normal distribution, an unpaired Student’s T-
test confirmed there was a significant increase in the concentration of cells 
isolated from the blood of CRPS patients compared to healthy controls (p = 
0.008). The average concentration of cells isolated from CRPS whole blood was 
1.23 x 106 (+/- SEM 0.058) cells/ mL of whole blood compared to 1.06 x 106 (+/- 
0.018) cells/ mL blood from healthy controls. CRPS participants P11 and P18 
had the highest concentrations of PBMCs with 1.76 and 1.78 x 106 cells/ mL, 
respectively. These two patients had a more chronic variation of CRPS, with 
duration of 21 and 19 years respectively.  
 
4.2.2. PBMC viability by Trypan Blue exclusion 
The viability of freshly isolated CRPS and healthy PBMCs, as measured by 
Trypan Blue exclusion, averaged 95.6% (+/- SEM 1.132) and 96.5% (+/- 0.374), 
respectively with no significant difference (Figure 4.2).  
 
4.2.3. Relationship of cellular recovery with duration of disease, severity and 
age 
Correlation analysis established there was no relationship between the PBMC 
concentration of CRPS with the duration of disease (p = 0.413); with the severity 
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of the condition (p = 0.114) or with the age of the CRPS participant (p = 0.439) 
in this study.  
 
 
Figure 4.1: Concentration of PBMCs (million per mL) of CRPS compared to healthy controls. CRPS 
PBMCs were isolated at a concentration of 1.23 x 106 (+/- SEM 0.058) compared to health controls that was 
a concentration of 1.059 x 106 (+/- 0.018). P11 and P18 had the two highest PBMC concentrations.  
 
 
Figure 4.2: Viability of PBMCs once extracted from buffy coat of whole blood. Measured by Trypan 
Blue and the use of a haemocytometer. P15 had the lowest viability with 78% followed by P18 with a 
viability of 86%, although the majority of patient PBMC viability edged 95.6%. All control viability was 
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4. 3. α-1AR expression analysis of PBMCs 
4.3.1. RNA extraction and purity, and cDNA synthesis 
The concentration (ng/ µL) of total RNA extracted from 1 x 106 PBMCs varied 
substantially across CRPS participants and healthy controls, although overall 
there were no significant differences between CRPS and healthy controls (Figure 
4.3). The average concentration of RNA extracted from CRPS PBMCs was 
39.77 ng/ µL (+/- SEM 3.899) compared to 34.66 ng/ µL (+/- 2.591) from 
healthy control PBMCs.  
 
The lowest concentration of RNA from any participant was 13.65 ng/µL 
extracted from healthy control C13. Therefore all samples were adjusted to 13.65 
ng/ µL of RNA, using the formulas shown in Section 3.4.2, prior to conversion to 
cDNA. As 15 µL of RNA was used for synthesis to cDNA, the amount of RNA 
needed for cDNA synthesis equated to 204.75 ng. The concentrations of RNA 
eluted from each CRPS and control participant, and the corresponding volumes 
needed for cDNA synthesis, are shown in Appendix 4.  
 
In terms of RNA quality, the A260/A280 protein and DNA contamination ratio 
averaged at 2.124 (+/- SEM 0.023) for CRPS patients and 2.152 (+/- 0.029) for 
healthy controls, whereas the A260/A230 salt contamination ratio averaged at 
1.394 (+/- 0.084) for CRPS and 1.311 (+/- 0.098) for controls (Figure 4.4).  
 
Chapter 4.                                                                                                                                Results 
 68 
  
Figure 4.3: Total RNA extraction from one million PBMCs in CRPS (average 39.77 ng/ µL (+/- SEM 
3.899) and healthy individuals (average 34.66 ng/ µL (+/- 2.591). There was no significant difference 
between the RNA concentrations from CRPS and healthy individuals (p = 0.282), although the data is 
spread from 13.65ng/ uL and 80.55 ng/ uL. 
 
 
Figure 4.4: RNA purity. A) A260/A280 ratio of RNA extractions representing protein/DNA 
contamination. RNA is considered pure above a ratio of 2.0. B) A260/230 ratio of RNA extractions 
representing salt contamination. RNA is considered pure above a ratio of 1.8.  
 
 
4.3.2. Relationship between RNA concentration and age 
Further analysis revealed that there was a significant correlation (p = 0.042) 
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participants’ age, with a Pearson correlation coefficient of -0.323. The linear 
regression between the two variables is shown in Figure 4.5, using a regression 




Figure 4.5: Linear regression model of RNA concentration and the participants’ age shows a negative 
correlation. With a goodness of fit of 0.104, RNA concentration= 0.4313 x age + 59.35.  
 
 
4.3.3. α1-AR gene expression analysis by qPCR 
For logistical reasons, analysis of α-1AR expression of all CRPS and control 
participants was divided into five separate qPCR runs over a three-day period. 
Each participant was tested for duplicate samples of α-1AAR, α-1BAR, α-1DAR 
and UBE2D2 house-keeping gene expression. The qPCR runs were as listed in 
Table 4.2. Each run included a positive control for each of the α-1AR TaqMan 
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assays (CHO-1A and HaCat cells – see Methods and Materials Section 3.4.4.), 
which had been optimised prior to participant analysis. 
 
Table 4.2: Samples acquired per qPCR run.  
 CRPS patient Healthy Control 
Run 1 P1 – P4  C1 – C4 
Run 2 P5 – P8 C5 – P8 
Run 3 P9, P11 – P13 C9, C11 – C13 
Run 4 P14 – P17 C14 – C17 
Run 5 P10, P18 – P20 C10, C18 – C20 
 
4.3.3.1 TaqMan qPCR optimisation 
To initially ensure that the commercial TaqMan assays were functional, 
fluorescent emission for each probe was measured by qPCR using confirmed 
positive and negative controls (CHO-1A cells for α-1AAR and HaCat cells for α-
1BAR and α-1DAR). Fluorescence emissions of each of the positive and negative 
assay controls are shown on a linear scale (Figure 4.6A) and on a logarithmic 
scale (Figure 4.6B). The Ct value was calculated from the threshold positioned 
on the logarithmic graph above the negative control “background” fluorescence 
and during the exponential phase of amplification of the positive controls (Figure 
4.6B). The threshold calculated was a value of 0.087 and was used consistently 
among all five experimental qPCR runs.  
 
The following sections describe the separate fluorescent curves and Ct values for 
the α-1AAR, α-1BAR, α-1DAR and UBE2D2 house-keeping gene optimisations.  
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4.3.2.1.1. α-1AAR qPCR optimisation using CHO-1A cells 
To confirm the use of CHO-1A cells as a positive control for α-1AAR, the Ct 
value for α-1AAR expression in transfected CHO-1A cells during optimisation 
was 22.31 with the Ct value for the non-transfected cell line (CHO) 32.02, 
confirming positive expression of human α-1AAR by the CHO-1A cells. A 
CHO-1A cDNA sample was subsequently included with all 5 of the qPCR runs 
as a positive control, where the average Ct value for α-1AAR expression across 
all 5 qPCR runs was 21.14 (+/- 0.740). Figure 4.6 shows the cycle curve for the 
positive CHO-1A compared to the non-transfected negative control CHO cells. 
 
Figure 4.6: Fluorescent signals for α-1AAR in positive CHO-1A cells and negative (non-transfected) 
CHO cells. Part A show the linear fluorescence of α-1AAR. Part B show the logarithmic fluorescence of α-
1AAR in relation to the threshold. Ct values for α-1AAR in CHO-1A and CHO were 22.31 and 32.02, 
respectively.  
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4.3.2.1.2. α-1BAR and α-1DAR qPCR optimisation using HaCat cells 
To confirm the use of HaCat cells as a positive control for α-1BAR and α-1DAR, 
the cycle curves for α-1BAR and α-1DAR using HaCat cell cDNA are shown in 
Figures 4.7 and 4.8, respectively. The Ct value for α-1BAR and α-1DAR 
expression in HaCat cells during optimisation was 32.19 and 33.13 respectively 
calculated from the threshold value of 0.087, with no fluorescence detected using 
the negative non-template control. A positive α-1BAR and α-1DAR HaCat cDNA 
sample was included with every qPCR run, where the average Ct value for α-
1BAR expression in HaCat cells across all 5 runs was 31.09 (+/- SEM 0.820) and 
32.67 (+/- 0.750) for α-1DAR. As shown in Figures 4.7 and 4.8, the cycle curves 
for α-1BAR and α-1DAR confirmed no expression of these genes for the non-
template control in either the linear or logarithmic scales.  
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Figure 4.7: Fluorescent signals for α-1BAR in HaCat cells compared to the non-template control 
(NTC) HaCat cells which show no fluorescence. Part A show the linear fluorescence of α-1BAR. Part B 
show the logarithmic fluorescence of α-1BAR in relation to the threshold. The Ct value for α-1BAR in 
HaCat cells was 32.19. 
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Figure 4.8: Fluorescent signals for α-1DAR in HaCat cells compared to the non-template control 
(NTC) HaCat cells which show no fluorescence. Part A show the linear fluorescence of α-1DAR. Part B 
show the logarithmic fluorescence of α-1DAR in relation to the threshold. The Ct value for α-1DAR in 
HaCat cells was 33.13. 
 
4.3.2.1.3. UBE2D2 qPCR optimisation using PBMCs 
The cDNA from PBMCS of CRPS participant P10 and control participant C10 
was used for optimisation of the UBE2D2 house-keeping gene qPCR. The 
average Ct value for UBE2D2 expression in PBMCs was 28.21 for P10 and 
28.88 for C10 calculated from the threshold as shown in Figure 4.9B.  There was 
no expression of UBE2D2 in the non-template control (NTC) as shown in Figure 
4.9A.   
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Figure 4.9: Fluorescent signals for UBE2D2 from P10 and C10 PBMCs compared to the non-template 
control (NTC) which show no fluorescence. Part A show the linear fluorescence of UB2D2. Part B show 
the logarithmic fluorescence of UBE2D2 in relation to the threshold. The average Ct value for UBE2D2 in 
PBMCs for optimisation was 28.54. 
 
4.3.2.2. Analysis of UBE2D2 house-keeping gene expression by PBMCs 
Expression of the UBE2D2 house-keeping gene was measured using duplicates 
of cDNA samples from all participants throughout the five qPCR assay runs. The 
Ct value was calculated as the cycle number of each sample at which the 
amplified signal crossed an arbitrary positive signal threshold that was consistent 
across all samples. The threshold line was determined from optimisation of the 
qPCR assays as described above and was set as a value of 0.087. The average Ct 
value for each of the qPCR runs is shown in Table 4.3, with a one-way ANOVA 
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test confirming no significant difference between each of the runs (p = 0.189). 
An unpaired Student’s T test also established there was no significant difference 
in the Ct values of UBE2D2 between CRPS patients (28.63 +/- 0.135) and 
healthy controls (28.47 +/- SEM 0.127).  
 
Table 4.3 Average Ct values of UBE2D2 expression of PBMCs from both healthy controls and CRPS 
patients across the 5 qPCR runs.  














4.3.2.3.  α-1AAR expression by PBMCs 
Of all the CRPS and control participants tested, only two samples (CRPS P15 
and control C12) returned positive for α-1AAR expression. The P15 duplicate 
samples had Ct values of 33.85 and 34.4 whereas C12 had duplicate Ct values of 
34.35 and 34.4. Figures 4.10 and 4.11 show the amplification curves, in both 
linear and logarithmic scales, of α-1AAR and UBE2D2 in C12 and P15, 
respectively. UBE2D2 Ct values for C12 were 28.08 and 28.07, and for P15 were 
27.68 and 27.83.  
 
 4.3.2.4. α-1BAR and α-1DAR expression by PBMCs 
No expression was observed for either α-1BAR or α-1DAR by PBMCs from 
either CRPS or healthy control participants.  
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Figure 4.10: α-1AAR amplification from PBMCs of C12. A) Shows the linear scale of fluorescent signal 
of α-1AAR compared to the house-keeping gene UBE2D2. B) Shows the logarithmic scale in relation to the 
threshold of 0.087. The Ct values of α-1AAR was 34.35 and 34.4 whereas UBE2D2 Ct values for C12 were 
28.07 and 28.08. 
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Figure 4.11: α-1AAR amplification from PBMCs of P15. A) Shows the linear scale of fluorescent signal 
of α-1AAR compared to the house-keeping gene UBE2D2. B) Shows the logarithmic scale in relation to the 
threshold of 0.087. The Ct values of α-1AAR was 33.85 and 34.4 whereas UBE2D2 Ct values for P15 were 
27.68 and 27.83. 
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4.4. PBMC subset analysis by flow cytometry  
4.4.1. PBMC viability  
4.4.1.1 Thawed cryopreserved cell viability as assessed by Trypan Blue 
exclusion  
Initially, prior to flow cytometry analysis the viability of thawed, cryopreserved 
cells was determined by Trypan Blue exclusion. Using this method, the average 
viability of PBMCs isolated from CRPS patients once thawed after 
cryopreservation was 61.05% (+/- SEM 3.424), which was significantly lower 
than for PBMCs isolated from healthy controls after cryopreservation (70.45% 
+/- 2.427; p = 0.031) (Figure 4.12). Both groups were significantly less viable 
after cryopreservation when compared to viability before cryopreservation. 
Viability of CRPS PBMCs dropped from 95.6% (+/- 1.132) to 61.05% (+/-3.424) 
(p <0.0001). Viability of healthy control PBMCs dropped from 96.5% (+/-
0.3735) to 70.45% (+/- 2.427) (p <0.0001). 
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Figure 4.12: PBMC viability determined by Trypan Blue after cryopreservation from CRPS and 
healthy individuals. The average viability of CRPS PBMCs was 61.05%, which is significantly less than (p 
value: 0.0310) the viability of PBMCs from healthy controls (average: 70.45%).  
4.4.1.2. Thawed cryopreserved cell viability as assessed by 7AAD staining and 
flow cytometry  
As an alternative to Trypan Blue staining for assessing cell viability, the antibody 
panel design allowed a 7AAD viability dye to be included to assess cell viability 
during flow cytometry acquisition. Viability stained by 7AAD was significantly 
different (p <0.0001) to that stained by Trypan Blue and recorded by the 
haemocytometer as shown in Table 4.4.  Using the 7AAD stain and flow 
cytometry, there was no significant difference in the viability between CRPS 
patient and control samples: the viability of CRPS PBMCs was 84.02% (+/- 
SEM 3.414) and healthy control PBMCs was 86.10% (+/- 1.548) (Figure 4.15). 
However, there was one obvious outlier; P18 (24.58% viable), which was 
subsequently excluded from further analysis. Figure 4.13 depicts the viability of 
PBMCs of the CRPS and healthy control groups once the outliers were removed. 
The average viability of PBMCs without outliers was 87.15% (+/- 1.442) for 
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Figure 4.13: Viability of PBMCs after cryopreservation with and without outlier measured by 7AAD. 
P18 PBMCs after cryopreservation were only 24.58% viable and were removed from data analysis, 
 
4.4.2. Optimisation of the flow cytometry multi-colour antibody panel 
4.4.2.1. Fresh PBMCs vs. frozen PBMCs  
For logistical reasons, ficoll-separated PBMCs were required to be stored frozen 
prior to analysis by flow cytometry. To assess the effect of freezing and thawing 
on the distribution of PBMC subsets, initially the forward scatter (FSC) and side 
scatter (SSC) of thawed cryopreserved PBMCs from one control (C10) were 
compared to that of PBMCs extracted from the same individual collected as fresh 
cells (Figure 4.14). This showed a slight increase in the proportion of monocytes 
from 6.25% to 10.40% after cryopreservation, with a slight decrease in the 
Table 4.4: Viabilities of PBMCs from CRPS and healthy individuals after cryopreservation by 
Trypan Blue and 7AAD exclusions. +/- SEM.   
 Viability after 
cryopreservation (%) (Trypan 
Blue) 
Viability after 
cryopreservation (%) (7AAD) 
CRPS 61.05 (+/-3.424) 84.02 (+/- 3.414) 
Healthy control 70.45 (+/- 2.427) 86.10 (+/- 1.548) 
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proportion of lymphocytes from 82.80% to 81.10%. Thawed-cryopreserved 
monocytes became more tightly compacted around a lower SSC, with FSC 
remaining similar. More debris (low SSC/FSC) was evident in non-
cryopreserved PBMCs compared to that of thawed-cryopreserved PBMCs, 
however there was a greater distinction between lymphocytes and debris in the 
sample that had not been cryopreserved compared to that of the thawed-
cryopreserved sample (Figure 4.14).  
 
Figure 4.14: FSC and SSC of frozen and thawed PBMCs. (A) in comparison to fresh (not frozen and 
thawed) PBMCs (B) of the same individual.  
 
4.4.2.2. Adjusting compensation using single-stained controls 
Prior to running the full antibody panel, cells stained with single antibodies were 
used to compensate for spectral overlap of fluorochromes, particularly those 
whose fluorescence was excited by the same laser. The fluorochromes FITC 
(CD16), PE (CD56), ECD (CD19), 7AAD (viability) and PE-Cy7 (CD14) all 
were excited by the blue laser; APC (CD4), A700 (CD8) and APC-A750 (CD3) 
by the red laser and BV421 (CD25) and Krome Orange (CD45) by the violet 
laser. Compensation values were set to remove spectral overlap for each 
antibody/fluorochrome into each fluorescent channel, as shown in Appendix 5.  
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4.4.3. Gating strategy for identification of PBMC populations 
A schematic diagram showing the PBMC populations analysed and their surface 
markers is shown in Figure 4.15. Using this strategy, the electronic gating 
strategy for identification of these subpopulations in CRPS and control 
participant PBMC is shown in Figure 4.16. This gating strategy was applied to 
the PBMC isolated from all participants (excluding the one sample that was low 
viability as assessed by 7AAD staining as described above), although minor 
changes were applied to account for population shifts between acquisition runs. 
According to this strategy, cells were first gated for expression of CD45 (a pan-
leukocyte marker) together with SSC to include granular cells (Fig. 4.16A), 
followed by gating for viable cells that were negative for 7AAD, which will only 
penetrate and label non-viable cells (Fig. 4.16B). Monocytes were then identified 
as CD14+ SSChigh (Fig. 4.16C) which were then separated into three populations 
(classical, intermediate and non-classical) based on CD16 and CD14 expression: 
CD14+ CD16- monocytes represent “classical” monocytes, whereas CD14+ 
CD16+ monocytes were split into two populations – CD14high “intermediate” 
monocytes and CD14low “non-classical” monocytes (Fig. 4.16D) (Wong et al., 
2012). The remaining PBMC populations were then gated as all cells that were 
CD14- “non-monocytes” (Fig. 4.16C). As shown in Figure 4.16E, B cells were 
identified by the expression of CD19 and not the pan-T cell marker CD3 (CD19+ 
CD3-). From this point, T cells were identified based on CD3 expression, but not 
CD56 (CD3+ CD56-), NK cells were identified based on CD56 expression and 
not CD3 (CD56+ CD3-) and NKT cells expressed both CD3 and CD56 (CD3+ 
CD56+) (Fig. 4.16F). The CD3+ CD56- T cells were then separated on the basis 
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of CD4 or CD8 expression into CD8+ CD4- T cells (CD8+ T cells), CD4+ CD8- T 
cells (CD4+ T cells) and CD4+ CD8+ T cells (double positive (DP) T cells) (Fig. 
4.16I). For both CD4+ and CD8+ T cells, the activation marker CD25 was also 
examined, identifying CD25+ activated T cells but also a potential population of 
“regulatory” T cells that express CD25 (CD4+ Treg and CD8+ Treg) (Fig. 4.16H). 
However, accurate identification of Treg cells requires additional markers (e.g. 
FoxP3), which were not possible to incorporate in this panel due to limitations on 
the number of fluorochromes that could be used with the Gallios flow cytometer. 
Finally, CD56+ CD3- NK cells (Fig. 4.16F) were further separated based on 
levels of CD56 expression into CD56bright and CD56dim NK cells (Fig. 4.16G). 




Figure 4.15: PBMC population sorting based on cell surface CD markers. CD45 is a standard leukocyte 
marker and is commonly used to separate leukocytes/PBMCs from whole blood. 7AAD negative cells 
isolated viable CD45 leukocytes. Monocytes express CD14 and varying levels of CD16 that further 
differentiates monocyte populations. CD14- cells account for lymphocytes, NK cells and NKT cells. CD19+ 
lymphocytes isolate B cells, where as CD19- separates all other cell types. CD19- CD3+ lymphocytes are T 
cells, which are further differentiated into CD4+ helper T cells, CD8+ cytotoxic T cells and CD4 CD8 
double positive T cells. T regulatory cells stem off of either CD4 or CD8 and express CD25. CD19- CD3+ 
CD56+ marks NKT cells, whereas NK cells are CD19- cells that only express CD3. NK cells can further be 
differentiated dependent upon level of expression of CD56.  
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Figure 4.16. Flow cytometry gating strategy from Kaluza analysis software used to determine PBMC 
populations as following Figure 4.15. 
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4.4.4. Analysis of PBMC populations in CRPS and control participants 
Table 4.5 shows an overview of the percentage composition of PBMCs, to be 
discussed throughout this section, in CRPS patients and healthy controls.  
 
Table 4.5: Summary of the major types of PBMCs, their percentages and p-value 
significance within CRPS and healthy groups (+/- SEM).  
 
 CRPS (% of 
PBMCs)  
Healthy (% of 
PBMCs)  
P value 
n value 19 20  
Viable cells (with outliers) 84.02 (+/- 3.414)  
 
86.1 (+/-1.548)  
 
0.5834 
Viable cells (minus 
outliers) 
87.15 (+/- 1.442)  86.1 (+/- 1.548)  0.6220 
Monocytes 13.52 (+/- 0.8819) 14.75 (+/- 1.102) 0.3951 
B cells 14.61 (+/- 1.365) 12.77 (+/- 1.135) 0.3031 
Total T cell 48.12 (+/- 1.941) 49.3 (+/- 1.433) 0.6250 
CD4 T cell 31.73 (+/- 1.662) 32.56 (+/- 1.642) 0.7235 
CD8 T cell 14.32 (+/- 0.9749) 14.27 (+/- 1.157) 0.9721 
NK cells 11.29 (+/- 1.116) 11.71 (+/- 0.6905) 0.7488 
NKT cells 5.838 (+/- 1.334) 4.342 (+/- 0.6668) 0.3149 
Ratio non monocytes: 
monocytes 




Total monocytes (CD14+ SSChigh) from CRPS patients constituted a mean of 
13.52% (+/- 0.882) of total PBMCs, compared to healthy controls, where 14.75% 
(+/- 1.105) of PBMCs were identified as total monocytes (Figure 4.17). Based on 
an unpaired Student’s T-test there was no significant difference between the 
percentage of monocytes in CRPS patients when compared to healthy controls.  
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Figure 4.17: Percentage of monocytes from total PBMCs in CRPS patients and healthy controls. A 
two-tailed T test showed no statistical significance of the monocyte percentage from CRPS patients 
(13.52%) when compared with healthy controls (14.75%). 
 
As described above (Figure 4.16) monocytes were divided into classical CD14+ 
CD16- monocytes and CD14+ CD16+ monocytes. These CD16+ monocytes were 
further divided into intermediate CD14high CD16+ monocytes and non-classical 
CD14low CD16+ monocytes (see Figure 4.16D). Classical CD14+ CD16- 
monocytes represented the majority of monocytes constituting 88.83% (+/- 
1.016) of CRPS monocytes and 90.19% (+/- 1.389) of healthy controls 
monocytes. Intermediate CD14high CD16+ monocytes were the next most 
frequent monocyte representing 8.97% (+/-0.841) of monocytes in CRPS patients 
compared to 7.53% (+/-0.987) in healthy controls. Non classical CD14low CD16+ 
monocytes were the least frequent monocyte, constituting only 1.94% (+/- 0.264) 
and 1.76% (+/- 0.498) in CRPS patients and healthy controls, respectively. As a 
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CD16- to CD14+ CD16+ (CD14high CD16+ and CD14low CD16+) monocytes, 
statistical significance was analysed by a one-tailed unpaired T-test (Ritz et al., 
2011). This revealed no statistical significance in the subpopulations of CD14+ 
CD16-, CD14high CD16+ and CD14low CD16+ between CRPS patients and healthy 
controls (Table 4.6). However, when the ratio of CD14+ CD16- to CD14+ CD16+ 
was assessed in this study, there were 9.74 (+/- 1.035) times more CD16- 
monocytes to CD16+ monocytes in CRPS patients, with a higher ratio (13.93 +/- 
1.84) of CD16- monocytes to CD16+ monocytes in healthy controls (Figure 
4.18). A one-tailed unpaired T test confirmed this was statistically significant (p 
= 0.029). However, when statistically analysed using a two-tailed unpaired T 
test, it was determined to not be significantly different (p = 0.058) (Table 4.6). 
  
 
Table 4.6: Subpopulations and percentage of total monocytes.   
 CRPS (% of 
monocytes) 
Healthy (% of 
monocytes) 
P value (one 
tailed) 
CD14+ CD16- classical 88.83 (+/- 1.016) 90.19 (+/-1.389) 0.219 
CD14+ CD16+ 
(intermediate + non 
classical)  
10.91 (+/- 0.982) 9.29 (+/- 1.418) 0.179 
CD14high CD16+ 
intermediate 
8.97 (+/- 0.841) 7.53 (+/- 0.988) 0.139 
CD14low CD16+ non 
classical 
1.94 (+/- 0.264) 1.76 (+/- 0.498) 0.378 
Ratio CD14+ CD16-: 
CD14+ CD16+  
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Figure 4.18: The ratio of CD14+ CD16- classical monocytes to CD14+ CD16+ monocytes 
(intermediate and non classical type). A one-tailed T test confirmed there was a significant decrease (p = 
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4.4.4.2. B cells 
Of total viable CD45+ leukocytes, B cells were identified as CD19+ CD3- as 
shown in Figure 4.16E. In CRPS participants, 14.61% (+/- 1.360) of PBMC were 
B cells compared to 12.77% (+/- 1.135) in healthy controls (Figure 4.19), which 




Figure 4.19: Percentage of B cells from total PBMCs from CRPS patients and healthy controls. No 
statistical difference shown. CRPS B cells constitute 14.61% of the PBMC population, whereas healthy 
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4.4.4.3. Total T cells and T cell subsets 
Total T cells were identified as CD3+ CD56- after gating for viable, CD14- 
CD19- cells as shown in Figure 4.16F. The mean percentage of total T cells in 
PBMC of CRPS participants was 48.12% (+/- 1.941) compared to 49.30% (+/- 
1.433) in healthy controls (Figure 4.20A), which was not statistically 
significantly different as determined by unpaired Student’s T test.  
 
For T cell subsets, CD4+ T cells constituted 32.56% (+/- 1.642) of total PBMC of 
healthy controls, compared to 31.73% (+/-1.662) for CRPS participants (Figure 
4.20B). Additionally, CD8+ T cells comprised 14.27% (+/- 1.157) of total 
healthy control PBMCs compared to 14.32% (+/- 0.975) in CRPS participants 
(Figure 4.20C). The differences between CD4+ T cells and CD8+ T cells in CRPS 
and control participants were not statistically significantly different as 
determined by unpaired Student’s T test.   
 
The percentage compositions of CD4+ T cells, CD8+ T cells, CD4+ CD8+ DP T 
cells, CD4+ CD25+ and CD8+ CD25+ within the total T cell populations are 
shown in Table 4.7. Again, as shown for percentages of total PBMC above, there 
was no significant differences for these T cell subsets between CRPS patients 
and healthy controls. In addition, there were 2.45 (+/- 0.230) times more CD4+ T 
cells than CD8+ T cells in CRPS participants, which was not statistically 
significantly different from healthy controls, who had a CD4:CD8 ratio of 2.61 
(+/- 0.251) (Table 4.7).  
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Figure 4.20: Percentage of T cells in PBMC population. A) Total (CD3+ CD56-) T cell percentage in 
PBMCs from CRPS patients (48.12% +/- 1.941) and healthy controls (49.30% +/- 1.433) was not 
statistically significantly different. The T cell population was split into CD4 (B) and CD8 (C) T cells. These 
were also not statistically significantly different in CRPS patients (CD4: 31.73%; CD8: 14.32%) when 
compared to healthy controls (CD4: 32.56%; CD8: 14.27%).  
 
 
Table 4.7: Summary of the types of T cells found in PBMCs and their composition within 
the T cell population (+/- SEM). 
 CRPS (% of T cells) Healthy (% of T cells) P value 
CD4+ helper T cells 65.56 (+/- 2.120) 66.11 (+/- 2.487) 0.888 
CD8+ cytotoxic T cells 30.04 (+/- 2.164) 28.84 (+/- 2.008) 0.687 
CD4+ CD8+ double 
positive 
0.76 (+/- 0.217) 0.72(+/- 0.315) 0.923 
CD4+ CD25+ T 
regulatory cells 
2.65 (+/- 0.320) 2.13 (+/- 0.256) 0.215 
CD8+ CD25+ T 
regulatory cells 
3.93 (+/- 0.959) 2.58 (+/- 0.536) 0.228 
CD4: CD8 ratio 2.45 (+/- 0.231) 2.61 (+/- 0.251) 0.656 
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4.4.4.4. NK cells  
Total viable NK cells were identified as CD56+ CD3- after gating for CD19- and 
CD14- cells as shown in Figure 4.16F. Of CRPS patients, NK cells constituted 
11.29% (+/- 1.116) of total PBMC compared to 11.71% (+/- 0.691) for healthy 
controls (Figure 4.21). As shown in Figure 4.16G, NK cells were further 
separated on the basis of CD56: CD56bright NK cells, which had a mean 
fluorescence intensity (MFI) for CD56 of 67.55 (+/- 1.782) and; CD56dim NK 
cells, which had a MFI for CD56 of 14.94 (+/- 0.485). The CD56dim NK cells 
were more frequent than the CD56bright NK cells in both CRPS patients and 
healthy controls, constituting 79.79% (+/- 2.188) and 79.88% (+/- 2.49) of total 
NK cells respectively (Figure 4.22A). The CD56bright NK cells were less 
frequent, representing only 3.04% (+/- 0.509) and 2.60% (+/-0.436) of total NK 
cells in CRPS and control participants respectively (Figure 4.22B). The 
differences between NK cells and NK cell subsets in CRPS and control 
participants were not statistically significantly different as determined by 
unpaired Student’s T test.  
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Figure 4.21: Percentage of NK cells from total PBMCs. CRPS patients (11.29%) were not statistically 




Figure 4.22: CD56 dim (A) and CD56 bright (B) subsets of NK cells.  CD56 bright constitute the 
majority of NK cell population in both CRPS (79.79%) and healthy (79.88%) participants compared to 
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4.4.4.6. NKT cells 
Total NKT cells were identified as CD56+ and CD3+ after gating for CD19- and 
CD14- cells as shown in Figure 4.16F. Of the total PBMC population of CRPS 
participants, 5.84% (+/- 1.334) were NKT cells compared to 4.34% (+/- 0.667) 
for control participants (Figure 4.23), which was not statistically different as 




Figure 4.23: Percentage of NKT cells from total PBMCs across all 36 samples acquired. The 
percentage of NKT cells within the PBMC population were not statistically significantly different in CRPS 
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5. Discussion  
The aim of this project was to examine the expression of α-1AAR, α-1BAR and 
α-1DAR mRNA in PBMCs isolated from whole blood of CRPS patients and 
healthy controls. The populations of PBMCs in the peripheral blood of CRPS 
patients and healthy controls were also assessed, and the relevant percentages of 
these populations were determined. One CRPS patient and one healthy control 
expressed low levels of α-1AAR mRNA. No other study participant expressed α-
1BAR or α-1DAR mRNA in their PBMCs. Analyses of PBMC populations 
showed there was an overall increase of the concentration of PBMCs isolated 
from whole blood of CRPS patients compared to healthy controls, and a shift 
towards an increase of the proportion of CD14+ CD16+ monocyte subpopulation 
was found. There was no significant difference of T cell subsets, B cells, NK 
cells or NKT cells between CRPS patients and healthy controls.  
 
5.1. Demographics of CRPS participants  
The CRPS patients in this study mirrored the characteristics of CRPS in previous 
studies. In this study, there were three times as many females studied than men 
(Sandroni et al., 2003; de Mos et al., 2007). The mean age of patients in this 
study was 51 years (+/- 10.82), where previous studies state CRPS patients 
commonly develop the condition between the ages of 37 and 52. However, the 
age of the patients in this study did not signify the age of the patient at diagnosis, 
rather that it was documented at the time of blood extraction. Therefore, if the 
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duration of disease in CRPS patients was accounted for, the average age of the 
CRPS patients at the time of diagnosis was 42.7 years.  
 
Fractures, sprains and surgery of a limb are the most likely events provoking 
CRPS onset (Veldman et al., 1993; Harden et al., 2010). This was reflective 
among the participants of this study, as 75% of CRPS patients reported one of 
these as their predisposing event. Tendon damage, hyperextension injury, 
dislocation and crush injury were among the other predisposing events in this 
study. Nerve conduction tests are commonly used in CRPS diagnosis for 
determination of nerve injury and distinguishing between CRPS types I and II 
(Borchers and Gershwin, 2014). However, several patients from this study had 
not had prior nerve conduction tests, thus subdividing patients into type I or type 
II could not be done. It is suggested that CRPS patients who immobilise their 
affected limb to assist in the healing of the injury are more likely to develop type 
I than type II, thus this study may have been able to speculate patients who were 
inconclusive of nerve injury but who had immobilised their limb to assist in 
healing as CRPS type I (Borchers and Gershwin, 2014; Wei et al., 2016). In this 
study, the upper extremity was affected in 60% of the cases compared to 40% of 
lower extremity cases, which correspond with previous studies (de Mos et al., 
2009). No children or adolescent CRPS cases were examined in this project 
where only rare cases (<10% of sufferers) have been reported previously (Wilder 
et al., 1992). In summary, the CRPS patients studied in this project were 
reflective of CRPS characteristics as described in previous studies.  
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5.1.1. The use of a clinical severity score in CRPS research  
Classifying CRPS patients on the basis of the severity of their condition can be 
used as a diagnostic aid to support criteria developed by the International 
Association for the Study of Pain (IASP) (Harden and Bruehl, 2005). Although 
not extensively used, the CRPS severity score (CSS) has emerged as a useful tool 
in recent years and could aid researchers in developing a clearer 
pathophysiological understanding of CRPS (Harden et al., 2010). Patients in this 
study were evaluated and tested for 13 possible symptoms (Appendix 1). The 
most severe CRPS patient had 12 of these 13 symptoms, and the least severe had 
5 of these 13 symptoms.  
 
One limitation of this study is that these patients were assigned a CSS at a single 
time point at the time of blood extraction. Therefore, this only documented the 
severity at one time point of their condition and did not take into account how the 
patients’ condition, or the type of symptoms, may have changed over time. A 
longitudinal study that observed patients over six years report 30% of chronic 
CRPS patients experience resolution of disease, 16% report progressive 
deterioration and the remaining 54% report stable symptoms (de Mos et al., 
2009). Thus it is expected that the nearly half of the CRPS participants studied in 
this project may have experienced a change in their condition since diagnosis. 
Additionally, another study reported that patients initially diagnosed with “warm 
type” CPRS are more likely to experience disease resolution than those 
diagnosed with “cold type” CRPS (Vaneker et al., 2005). “Warm type” CRPS is 
the most common presentation in the acute CRPS phase, and is consistent with 
an acute inflammatory response. Despite this, this study did not categorise 
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patients into warm type or cold type CRPS. If, in future, the CSS could be 
utilised to capture the time point at which CRPS patients may begin to 
experience disease resolution, or where the condition intensifies, we may be able 
to grasp a better understanding of how this inflammatory process may switch off 
and resolve, or progress to chronic CRPS.  
 
5.1.2. Correlation between disease severity and duration 
Although this study demonstrated no correlation between the duration of disease 
and disease severity as measured by CSS, this study was limited in its ability to 
accurately describe this relationship. In order to determine if there was a 
relationship between the severity of CRPS with its duration, the same patient 
would need to be monitored over a period of time. This study correlated the CSS 
of all CRPS patients with the varied disease durations. As half of CRPS patients 
are expected to experience a change in condition, and self-reported symptoms 
and pain ratings used in the CSS developed are subjective, it may be inaccurate 
to assume there was no correlation between severity and duration of disease (de 
Mos et al., 2009). To confirm this, a larger scale study would need to be 
conducted to assess the severity of several CRPS patients over an extended 
period of time. 
 
5.1.3. Correlation between age and total RNA concentration 
Correlation analysis from this study showed there was a negative relationship 
between a participant’s age and the amount of RNA extracted from 1x106 
PBMCs. Previous studies suggest that this decline in total RNA levels 
corresponds to a decline in growth, protein synthesis and metabolic rate with age 
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(Chomczynski et al., 2016; Tahoe et al., 2003). This decline in RNA 
concentration did not affect the outcome of this study as the volume of total 
RNA used to qPCR analysis was modified across all samples to allow the same 
concentration of RNA to be used. However, since low levels of α-1AAR were 
detected in only two participants of this study and no α-1AR expression 
elsewhere, levels of α-1AR may have been more detectable with a larger total 
RNA concentration. Therefore, using a greater concentration of total RNA for α-
1AR analysis of PBMCs may need to be used in future. 
 
5.2. Analysis of α-1AR mRNA expression by PBMCs in CRPS 
Previous studies have shown an increase in density, or responsiveness of α-1AR 
in keratinocytes and nociceptors of CRPS patients’ affected limb that are subject 
to sentisitisation by circulating catecholamines and cytokines (Dawson et al., 
2011; Drummond et al., 2014a; Drummond et al., 2014b). This likely contributes 
to the malfunctioning of the SNS and the release of neuropeptides that evoke 
vasodilation and protein extravasation, facilitating local inflammation (Borchers 
and Gerschwin, 2014; Birklein and Schlereth, 2015). Additionally, in other 
chronic inflammatory diseases, the expression of α-1AR in leukocytes is 
upregulated (Ricci et al., 1999; Szentivanyi et al., 1979; Wahle et al., 1996; 
Heijnen et al., 1996). As CRPS patients commonly present with persisting 
inflammation, and as it is known that α-1AR expression is upregulated in other 
cell types in CRPS, the expression of α-1AR on PBMCs in CRPS was assessed. 
From this study, no difference in expression of α-1AR mRNA of PBMCs from 
CRPS patients when compared to healthy controls was observed. Low levels of 
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α-1AAR mRNA expression of PBMCs in one CRPS patient and one healthy 
control, and no mRNA expression of α-1BAR or α1D-AR in any of the study 
participants were shown. The detection of α-1AAR from CHO-1A cells, and α-
1BAR and α1D-AR from HaCat cells, during optimisation and throughout the 
qPCR acquisitions supported the validity of these results. Additionally, the 
A260/A280 ratios of the RNA samples were consistently above 2.0, indicating 
no protein or DNA contamination (Desjardins and Conklin, 2010). However, the 
A260/A230 ratio was inconsistent with the recommended 1.8 value. A ratio 
below 1.8 in this respect indicates salt contamination from the washing step of 
the RNA extraction and may affect RNA integrity to convert to cDNA 
(Desjardins and Conklin, 2010). As the house-keeping gene UBE2D2 showed 
consistent Ct value across the qPCR analysis in any sample, I was confident that 
any salt contamination of extracted RNA did not affect the quality of cDNA used 
in this study. 
 
A confounding issue was the non-transfected CHO cell line used as a negative 
control for α-1AAR optimisation showed low levels of endogenous α-1AAR 
expression. The CHO cell line was derived from Chinese hamster ovary 
epithelium. Since the CHO-1A cell line is transfected with the human α-1AAR 
gene, this primer may have detected a conserved genetic sequence of the hamster 
and human α-1AAR gene in the non-transfected CHO cell negative control. The 
level of α-1AAR expression in CHO cells compared to CHO-1A cells was 
substantially lower, thus it was used as a negative control. It would have been 
more appropriate to use a non-template control (NTC). However, this cDNA was 
a gift from another laboratory and we were not provided with a NTC alternative. 
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Despite these concerns, I was confident that the primers used in this study 
specifically detected α-1AR of PBMCs from CRPS patients and healthy 
controls.  
 
As there was no significant difference in α-1AR mRNA expression between 
CRPS patients and healthy controls in this study, I concluded that α-1AR mRNA 
expression of PBMCs was independent from CRPS. However, two female 
participants (one CRPS and one control) did show α-1AAR expression. The 
CRPS participant was 24 years of age and the healthy control was 45 years of 
age. As there were several other participants within these age ranges, and the 
majority of participants were female, I also concluded that the expression of α-
1AAR in PBMCs was independent of age and sex in this study. In order to 
confirm this however, a larger number of samples would need to be analysed, 
which was beyond the scope of this project.  
 
5.2.1. Expression of α-1AR subtypes in PBMCs  
Previous studies assessing the expression of α-1AR in leukocytes showed mixed 
results (Casale and Kaliner, 1984; Kavelaars, 2002; Rouppe van der Voort et al., 
2000). The majority of studies suggested that there was no baseline expression of 
α-1AR in leukocytes; rather that it is only expressed following an inflammatory 
stimulus or within chronic inflammatory diseases (Ricci et al., 1999; Szentivanyi 
et al., 1979; Wahle et al., 1996; Heijnen et al., 1996). Although this project 
predicted that CRPS might have been an example of a chronic inflammatory 
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disease provoking the expression of α-1AR in PBMCs, this hypothesis was not 
supported. 
 
In order to fully assess α-1AR expression by PBMCs of CRPS patients, it may 
be necessary to identify the inflammatory stimulus provoking CRPS onset. This 
study assessed α-1AR expression some time (up to 20+ years) after the initial 
injury, which may not have been an appropriate time to assess α-1AR expression 
of PBMCs in CRPS patients. A previous study indicated that the expression of α-
1AR in leukocytes might be subject to change dependent on noradrenaline levels 
in the patients’ sera (Kalkoff et al., 2008). By examining cardiac surgery patients 
pre- and post surgery, they found that patients who had high and mid levels of α-
1AR and high levels of noradrenaline in leukocytes before surgery, showed a 
decrease in α-1AR expression post surgery (Kalkoff et al., 2008). This suggests 
that CRPS patients who may had previously expressed α-1AR in leukocytes at 
the time of injury, may not express it now, some time after the original 
inflammatory stimulus. This concept may also be applied to those participants 
who showed α-1AAR in PBMCs. Although undocumented, these participants 
may have experienced an inflammatory stimulus leading up to blood extraction 
resulting in α-1AAR expression on PBMCs. In order to validate this claim, α-
1AAR expression in PBMCs from these patients would need to be reassessed 
some time later. 
 
An alternative approach would include stimulating isolated PBMCs from CRPS 
patients and healthy controls in vitro with an inflammatory stimulus and then 
examining α-1AR expression. Previous in vitro studies that assessed α-1AR 
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expression on PBMCs used a T cell mitogen phytohemagglutinin (PHA) or 
lipopolysaccharide (LPS) as an inflammatory stimulus (Casale and Kaliner, 
1984; Kavelaars, 2002; Rouppe van der Voort et al., 2000). Cytokines and other 
inflammatory mediators are known to regulate the expression of α-1AR from 
PBMCs. For example, one study found that when the THP-1 monocyte line was 
cultured in the presence of IL-1β or TNF-α, the expression of α-1AAR was 
upregulated and the expression of α-1DAR was reduced. (Heijnen et al., 2002). 
Since CRPS patients have increased levels of pro-inflammatory cytokines in 
their sera, it would be interesting to see if differing levels of these cytokines in 
vitro affect the levels of α-1AR expression in PBMCs following an 
inflammatory stimulus (Schinkel et al., 2006; Uceyler et al., 2007).  
 
Furthermore, incubating LPS-stimulated PBMCs that express α-1AR with 
noradrenaline activates ERK-2 (Rouppe van der Voort et al., 2000). This kinase 
targets transcription factors that regulate the production of cytokines. Co-
incubation of noradrenaline with an α-1AR antagonist completely blocks the 
noradrenaline effect. Additionally, cells that do not express α-1AR do not 
respond to noradrenaline with increased ERK-2 activation (Kavelaars, 2002). 
This indicates that noradrenaline induced ERK-2, through α-1AR, enhances 
immune activity by increased cytokine production. As increased cytokine 
production is evident in CRPS patients, future studies could also assess the effect 
of noradrenaline on inflammatory stimulated-PBMCs that have already been 
induced to express α-1AR by analysing cytokine production.  
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5.2.2. α-1AR expression may be masked in minority PBMC populations  
Another possible reason for the failure to detect α-1AR expression by PBMC in 
this study is that the mRNA of α-1AR was only expressed by a subset of PBMC 
populations. Studies have shown that α-1AR is expressed in monocytes, which, 
from the results of this study, were found to be in the minority of the PBMC 
populations (13.5% of CRPS and 14.75% of healthy control PBMC) (Heijnen, 
2002; Takahashi, 2005). If the monocytes from the participants in this study 
expressed α-1AR, this could have been masked by the greater proportion of non-
monocytic PBMCs not expressing α-1AR. In this case, it would be advantageous 
to be able to isolate individual PBMC subpopulations to assess their α-1AR 
mRNA expression. In future studies, the antibody panel used in this study could 
be redesigned to include fluorescently labeled (BODIPY) prazosin, a specific α-
1AR antagonist (O’Connell et al., 2014; Hirasawa et al., 1996; Calzada and de 
Artinano et al., 2001; Waugh et al., 1999; Marrow and Crease, 1986). Using the 
flow cytometry approaches described in this study, the separate PBMC 
populations could then be analysed to detect α-1AR at the protein level. There 
are several limitations to this approach, however. Firstly, the 10-colour flow 
cytometry panel used in this study would need to be redesigned to allow the 
inclusion of BODIPY-prazosin. Secondly, prazosin has equal affinity for α-
1AAR, α-1BAR and α-1DAR (Calzada and de Artinano et al., 2001; Waugh et al., 
1999; Marrow and Crease, 1986). This means we would not be able to 
differentiate between the α-1AR subtypes. Thirdly, although α-1AAR and α-
1BAR are extracellular proteins, α-1DAR is entirely an intracellular protein. 
BODIPY-prazosin is used to identify extracellular proteins, thus the analysis of 
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extracellular proteins (and not intracellular) would inaccurately reflect the level 
of α-1AR expressed (McGrath et al., 1999; Mackenzie et al., 2000).  
 
A second alternative for differentiating α-1AR expression among PBMC 
populations involves using technology that is more recent. Prime Flow 
(Invitrogen, ThermoFisher) is a technology that combines cell surface and 
intracellular protein analysis using fluorescently labeled monoclonal antibodies, 
with mRNA analysis as measured by flow cytometry. Cell surface (and 
intracellular) markers are labeled with antibody as used in the flow cytometry 
strategy for this project. These cells are then fixed and permeabilised to allow for 
hybridisation of gene-specific probes with the RNA transcript of interest. Rather 
than amplifying the target transcript as with RT-PCR and qPCR techniques, a 
pre-amplifier is used to amplify the signal of the probe-RNA hybrid. The 
fluorescence of this hybridisation is then built upon by continual hybridisation 
with the pre-amplifier with the addition of a fluorescently labeled probe. This 
approach could potentially assess α-1AAR, α-1BAR and α-1DAR mRNA 
expression, along with cell surface marker expression, simultaneously in PBMC 
populations to allow analysis of α-1AR subset expression in subsets of PBMC 
(Soh et al. 2016).  
  
5.2.3. Relative shift of β-2AR to α-1AR expression in PBMCs 
In addition, several studies suggest that α-1AR expression in PBMCs is 
regulated by β2 adrenergic receptors (β-2AR), particularly after prolonged 
exposure to AR agonists (Wahle et al., 1996; Goebel et al., 2010). This could 
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suggest that rather than an overall change in expression of α-1AR in PBMCs, 
there could be a change in the ratio of β-2AR to α-1AR. Noradrenaline inhibits 
the release of pro-inflammatory mediators through β-2AR (Grisanti et al., 2011). 
Thus, given that pro-inflammatory mediators are increased in the plasma of 
CRPS patients, we would expect to see a decrease in the level of β-2AR 
responding to noradrenaline (Schinkel et al., 2006; Uceyler et al., 2007). In a 
previous study, a human monocytic cell line (THP-1) known to express α-1AR 
was cultured with the β-2AR agonist terbutaline and shown to increase α-1BAR 
and α-1DAR mRNA, without changes in the α-1AAR (Rouppe van der Voort, 
1999). These findings suggest that noradrenaline may regulate the expression of 
α-1AR in the immune system via binding to β-2AR that are constitutively 
expressed on most immune cells (Kavelaars, 2002). Thus, any future studies 
involving AR expression of PBMCs in CRPS could incorporate β-2AR mRNA 
analyses or stimulation in their study design.  
 
5.3. PBMC subset analysis by flow cytometry  
Using 10-colour flow cytometry analysis of PBMC subsets from CRPS and 
control participants, there were no significant differences in the relative 
percentages of any of the PBMC subpopulations identified between CRPS 
patients and healthy controls. However, there was a statistically significant 
increase in the total number of PBMCs per mL of whole blood in the CRPS 
patients compared to the healthy controls, and a shift of CD14+ CD16- to CD14+ 
CD16+ monocytes in CRPS patients, which will be discussed in the following 
sections.  
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5.3.1. Viability and integrity of PBMCs for flow cytometry analysis  
Due to the constraints of this project, PBMCs isolated from fractionated blood of 
CRPS patients and healthy controls were cryopreserved until flow cytometry 
analysis. Results showed a significant decline in cell viability following 
cryopreservation both by Trypan Blue and 7AAD. Interestingly however, there 
was also a significant difference in viability measured by these two techniques. 
Trypan Blue analysis showed a significant difference between the viability of 
CRPS patients (61.05%) when compared to healthy controls (70.45%), which 
was different again to 7AAD analysis. This showed viabilities of 84.02% and 
86.10% for CRPS patients and healthy controls, respectively.  As 7AAD was 
incorporated into the antibody panel of flow cytometry analysis, it measured the 
whole PBMC population of each sample in comparison to Trypan Blue, which 
only measured one hundredth of the amount. Therefore, viability analysis by 
7AAD is expected to be more accurate than that by Trypan Blue. Using 
viabilities produced by 7AAD, there was one obvious outlier (P18: viability 
24.58%). As the viability of this sample could affect the integrity of the PBMCs, 
it was excluded from PBMC percentage analysis. 
 
Furthermore, the side scatter (SSC) and forward scatter (FSC) of cryopreserved 
PBMCs was plotted and compared to that of freshly- obtained PBMCs. The 
results show that there was a slight increase in the percentage of monocytes in 
the cryopreserved sample in comparison to the fresh sample, but no change in the 
percentage of lymphocytes. This could suggest that the loss in viable cells may 
have obtained from the lymphocyte population. However, as the plots show no 
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significant loss in cell populations, and all the PBMCs analysed by flow 
cytometry all were cryopreserved, I concluded this did not affect the outcome of 
results from this study.  
 
5.3.2. Increased total PBMC count of CRPS patients 
The results from this study showed CRPS patients have a higher total PBMC 
count when compared to healthy controls, but no differences in the counts of 
PBMC subpopulations. Correlation analysis of this study also showed there was 
no relationship between the concentrations of PBMCs isolated from CRPS 
patients and the severity of the condition, the duration of disease and the age of 
the participant. Often an increased PBMC count is used in the identification of 
inflammatory diseases as well as a prognostic parameter for monocyte leukaemia 
and multiple myeloma (Shin et al., 2013; Wu et al., 2011). Several studies have 
identified an association between increased PBMCs in the peripheral blood and 
poor outcomes with patients with heart failure, intracerebral haemorrhage, 
atherosclerosis and thrombosis, where subsets of PBMCs are involved in tissue 
damage as well as monocyte mediated pathways of inflammation and apoptosis 
(Greene et al., 2012; Walsh et al., 2015; Chapman et al., 2004; Rezende et al., 
2014; Yin et al., 2003.).  
 
One study found that a high PBMC count was associated with a loss in bone 
marrow density of elderly men, which was positively related to destructive bone 
diseases such as psoriatic arthritis (Lin et al., 2016). In addition, the sympathetic 
nervous system, and in particular α-1AR signalling, may play a role in the 
regulation of bone marrow density and proliferation of PBMC progenitors 
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(Maestroni et al., 1992; Maestroni and Conti, 1994). Chemical sympathectomy 
by 6-hydroxydopamine (6-OHDA) significantly increased the number of 
peripheral blood leukocytes after syngeneic bone marrow transplant (Maestroni 
et al., 1992). The same study showed that prazosin, a potent α-1AR antagonist, 
can mimic and extend the effect of 6-OHDA with an additional rapid and 
significant increase of platelets, bone marrow granulocyte-macrophage colony 
forming units (GM-CFU) (the precursors for monoblasts and myeloblasts) and 
nucleated spleen cells. Furthermore, the α-1AR agonists noradrenaline and 
methoxamine can directly inhibit the in vitro growth of GM-CFU, while 
prazosin, and other α-1AR antagonists such as phentolalmine can counteract this 
noradrenaline effect (Maestroni and Conti, 1994). Mechanical denervation 
results in significant mobilisation of cells into the peripheral blood within 24 
hours, with a particular increase in progenitor cells (Afan et al., 1997). This 
demonstrates that α-1AR are present on bone marrow cells and participate in the 
regulation of hematopoiesis and proliferation. It also shows that the nervous 
system plays a selective role in the mobilisation of cells into the peripheral 
blood, which can ultimately result in an overall increase in cellular PBMC 
concentrations. For technical reasons, it would be difficult to assess α-1AR 
expression in cells of the bone marrow in CRPS patients. However, future 
studies may be able to target immature peripheral cells or progenitor cells in the 
periphery in conjunction with the previously mentioned addition of BODIPY-
labeled prazosin into the antibody panel, to grasp a better understanding of this 
concept. Markers such as CD133, CD34 and CD38 are expressed on myeloid and 
lymphoid precursor cells that subside during maturation (Attar, 2014).  
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Additionally, the flow cytometry strategy used in this study only assessed the 
relative number of cells within a sample as a percentage of total PBMC. An 
alternative approach would be to assess the absolute number of subsets of cells 
within a sample using Tru Count tubes (BD Biosciences, San Jose, CA). Using a 
Tru Count tube decreases the variability of the percentages of cell populations 
assessed as it determines the overall number of PBMCs, rather than a specified 
number (Schnizlein-Bick et al., 2000). By adding a specified number of 
microbeads to a sample, the absolute cell number can be determined by 
comparing the number of stained cellular events to the absolute number of bead 
events as counted by the flow cytometer. This would provide a more accurate 
measure of total numbers of each PBMC subset.  
 
5.3.3. Altered  CD14+ CD16- to CD14+ CD16+ monocyte ratios 
The 10-colour flow cytometry panel used in this project included a series of 
conjugated monoclonal antibodies that identified CD4+ T cells, CD8+ T cells, 
CD4+ CD8+ double positive (DP) T cells, CD4+ CD25+ activated/regulatory T 
cells, CD8+ CD25+ activated/regulatory T cells, B cells, NK cells, NKT cells and 
monocytes, however there were no statistically significant differences in the 
percentage of these cell types in the PBMC of CRPS patients when compared 
with healthy controls. These results are in agreement with the study of Ribbers 
and colleagues who reported no association with lymphocyte subpopulations in 
CRPS type I, and the study of Kaufman and colleagues who reported no changes 
in the percentages of CD8+ T cells, NK cells and B cells in CRPS patients 
(Ribbers et al., 1998; Kaufmann et al., 2007). 
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However, the ratio of CD14+ CD16- monocytes to CD14+ CD16+ monocytes in 
this study was lower in CRPS participants (9.742 +/- 1.035) when compared to 
healthy controls (13.93 +/- 1.84). As Ritz and colleagues have performed this 
analysis before and found a significant decrease in the ratio of CD14+ CD16- to 
CD14+ CD16+ monocytes, a one-tailed unpaired Student’s T test was used in this 
study and also confirmed a significant decrease in this ratio (p < 0.05) (Ritz et 
al., 2011). An unpaired T test, rather than paired T test, was used because 
although the patients were aged and sex matched with healthy controls, these 
sample groups were independent. It became evident throughout this project that 
other factors, such as individual variability, other inflammatory stimuli and 
unknown pre-existing conditions, may have contributed to the results produced 
in this project. Furthermore, using a two-tailed unpaired T test to confirm this 
significance showed that this relationship was not quite significant (p = 0.058). 
Possibly an n value of 19 for CRPS patients and 20 for healthy controls in this 
study could be a reason that this did not reach statistical significance, and in 
future an increased sample size could more accurately assess differences in this 
ratio.  
 
The CD16+ monocytes represent a potent antigen-presenting and pro-
inflammatory subpopulation of monocytes that have been shown to increase in 
inflammatory conditions (Radwan et al., 2016). They are a sole producer of the 
pro-inflammatory cytokine TNF-α, which CD16- monocytes fail to produce, and 
are also involved in T cell activation (Wong et al., 2012) More recently, this 
group of monocytes have been further classified into CD14high CD16+ 
(intermediate monocytes) and CD14low CD16+ (non classical monocytes). This 
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study found no difference in the percentages between the two CD16 expressing 
monocytes of CRPS patients and healthy controls, although many studies report 
difficulty in identification of these two subsets by flow cytometry (Wong et al., 
2012). Novel analysis show that intermediate type monocytes express the same 
level of CD14 as classical CD16- monocytes, whereas non-classical monocytes 
express CD14 at a much lower level (Wong et al., 2012). This gating strategy 
used in this study accounted for this, however as the percentage of these 
populations are so small, it may have not been entirely accurate. Furthermore, in 
CRPS, it has been shown that an increase in CD16+ monocytes is not correlated 
with the overall pain level of patients, but rather is correlated with patients who 
suffer from cold allodynia (Ritz et al., 2011). Interestingly, blocking α-1AR with 
a potent antagonist in CRPS patients inhibits dynamic allodynia, this can further 
suggest α-1AR expression on these cell subsets (Drummond et al., 2016). 
 
5.3.4. Limitations of the flow cytometry panel  
Another limitation of the flow cytometry strategy use in this study was that the 
panel was limited to only assess the most common subsets of PBMCs. Dendritic 
cells (DCs) are another type of PBMC involved in regulating the inflammatory 
response. They are antigen-presenting cells (APCs) that capture, process and 
present antigens through to naïve T cells, are thought to be involved in the 
functioning and maintaining of tolerance and maintain immune memory in 
tandem with B cells (Weider, 2003). Dendritic cells can derive from two 
lineages: myeloid DCs evolve from monocytes, whereas plasmacytoid DCs 
develop directly from hematopoietic stem cells. Myeloid DCs differentiate from 
monocytes in the presence of pro-inflammatory TNF-α and IL-4 and typically 
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express antigens CD11c, CD13, CD33 and CD11 but lack monocyte antigens 
CD14 and CD16. Plasmacytoid DCs lack myeloid antigens and are distinguished 
by CD13, CD303 and CD304. These antigens can all be targeted for flow 
cytometryic analysis (Collin et al., 2013). Co-stimulatory molecules CD80 and 
CD86 are also expressed, which are upregulated during activation. Since DCs are 
APCs, the major-histocompatibility complex class II (MHC II), which is 
involved in antigen presentation, is also a common target for flow cytometric 
analysis. Epidermal DCs (Langerhans cells) have been shown to be increase in 
the skin of CRPS patients, and to have upregulated α1-AR (Calder et al., 1998; 
Seiffert et al., 2002; Kavelaars, 2002). It was beyond the scope of this project to 
assess DCs in CRPS peripheral blood as this would have required expansion of 
the commercial flow cytometry panel beyond the 10-colour limit of the flow 
cytometer, however a future study could alter the flow cytometry strategy in this 
project to incorporate DC markers in the antibody panel, or use additional panels.  
 
5.3.5. Limitations of the PBMC isolation method 
The density gradient (Lymphoprep) isolation solution used in this project only 
isolated mononuclear cells from peripheral blood; polynuclear granulocytes have 
a higher density and therefore submerged to the bottom. However, there is a 
small chance of immature granulocyte contamination (1-5% of total cell 
number). The appearance of immature granulocytes in the peripheral blood 
indicates an early-stage response to infection, inflammation or isolation of other 
stimuli of the bone marrow (Senthilnayagam et al., 2011). The antibody panel 
used in this study did not stain for immature granulocytes, thus the proportion of 
immature granulocytes in the periphery was undetermined.  
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Mature granulocytes (neutrophils, eosinophils and basophils) were not isolated 
using this isolation procedure from whole blood. Neutrophils are decreased in 
CRPS patients which was shown to correlate with increased levels of stress 
hormone (Kaufmann et al., 2007). This suggests that CRPS patients have an 
impaired innate immunity, which may result in an adaptive immune response and 
chronic inflammation. In order to asses this however, in future it may be 
advantageous to analyse unfractionated blood and incorporate granulocyte 
markers into the antibody panel, or construct a panel assessing mononuclear 
cells, and a panel assessing polynuclear cells such as granulocytes. 
 
5.4. Future directions 
The results from this and other studies suggest that a number of factors regulate 
α-1AR expression, and that several reasons could explain why only two 
participants (one CRPS and one control) showed α-1AAR expression in this 
study. With previous studies suggesting α-1AR may only be expressed on 
PBMCs after an inflammatory stimulus, in future a more advanced study 
incorporating in vitro analyses of α-1AR of CRPS patient PBMCs following 
experimental inflammatory stimuli (e.g. lipopolysaccharide or T cell mitogens) 
and/or co-incubation with noradrenaline or pro-inflammatory cytokines could be 
informative. Utilising the CSS, and by receiving samples from patients over a 
period of time, documenting the change in their condition may also provide a 
clearer understanding of the changes with time of the underlying inflammatory 
response. Additionally, since only few populations of PBMCs are known to 
express α-1AR following inflammatory stimulus, it would be advantageous to 
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distinguish between PBMC populations during α-1AR analysis using a modified 
flow cytometry strategy incorporating fluorescently labeled BODIPY-prazosin 
into the antibody panel, sorting individual PBMC subsets for PCR analysis, or 
using the more technologically advanced Prime Flow strategy to detect mRNA in 
PBMC subsets by flow cytometry. Monocytes have been one type of PBMC 
shown to express α-1AR mRNA, and as shown in this and previous studies; the 
ratio of CD14+ CD16- to CD14+ CD16+ is increased in CRPS patients, which 
indicates a pro-inflammatory response. The results from this study also showed 
an overall cellular increase in PBMC of CRPS patients that could further indicate 
the problem arises from progenitor cells within the bone marrow. For technical 
reasons, it would be difficult to assess cells within the bone marrow of CRPS 
patients, however a future study could incorporate the use of activation markers 
or progenitor cell markers into this modified antibody panel.  
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6. Conclusion  
This study established no difference in the expression of α-1AR mRNA of the 
total PBMC population isolated from whole blood of CRPS patients when 
compared to healthy controls. It did, however, show low level of α-1AAR mRNA 
expression in one CRPS patient and one healthy control. In addition, this study 
showed no statistically significant difference in the percentages of CD4+ T cells, 
CD8+ T cells, CD4+ CD8+ T cells, CD4+ CD25+ activated/regulatory T cells, 
CD8+ CD25+ activated/regulatory T cells, B cells, NK cells and NKT cells of 
CRPS patients when compared to healthy controls, although an increase in the 
concentration of total PBMCs isolated from whole blood of CRPS patients and a 
shift to CD16+ from CD16- monocytes was found. In conclusion, based on the 
data generated, α-1AR expression of overall PBMC population is independent 
from that of CRPS, but was limited due to the inability to differentiate PBMC 
populations during this analysis. The increased PBMC concentration of CRPS 
patients and the shift to pro-inflammatory CD14+ CD16+ monocytes provide 
preliminary data that the aberrant inflammatory response of CRPS may stem 
from increased cell proliferation in the bone marrow that is regulated by the 
sympathetic nervous system via α-1AR. 
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Appendix 2: Bioline Isolate II RNA Mini Kit  
 
Table A2: Bioline Isolate II RNA Mini Kit contents 
Kit Contents Description 
ISOLATE II Filter (violet) Used to filter lysate once it was 
homogenized and reduces lysate 
viscosity.  
ISOLATE II RNA Mini Columns 
(blue) & Collection Tubes 
Used for binding RNA to silicon 
membrane and steps throughout 
washing 
Collection Tubes Eluted RNA collection tube 
Lysis Buffer RLY Contains guanidinium thiocyanate 
used for lysing cells for RNA 
extraction 
Wash Buffer RW1 Contains guanidinium thriocyanate 
and ethanol. Used for washing salts 
once RNA bound to silicon membrane. 
Wash Buffer RW2 Concentrate. Contains added ethanol. 
Used for washing residual salts/ 
Membrane Desalting Buffer MEM Contains guanidinium thiocyanate and 
ethanol. Desalts the silicon membrane 
before addition of DNase I. Salt 
reduces DNase I reactivity. 
Reaction Buffer for DNase I RDN Activates DNase I. 
DNase I, RNase-free (lyophilised)  Digests genomic DNA to allow elution 
of pure RNA. 
RNase-free Water Ensures integrity of RNA. 
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Appendix 3: Bioline SensiFAST cDNA synthesis kit  
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Appendix 4: RNA extraction concentrations from all 
samples and corresponding volumes used for cDNA 
synthesis  
Table A4: Breakdown of total RNA concentration (ng/µL) from the 40 participants and the 
corresponding volumes of RNA that equates to 204.75ng of RNA. 
Patient Concentration 











P1 42.05 4.87 C1 53.9 3.8 
P2 22.75 9 C2 30.95 6.62 
P3 62.9 3.26 C3 30.3 6.76 
P4 31.5 6.5 C4 28.1 7.29 
P5 25.75 7.95 C5 22 9.31 
P6 18.2 11.25 C6 20.65 9.91 
P7 26.8 7.64 C7 30.4 6.73 
P8 37.6 5.44 C8 28 7.31 
P9 24.1 8.49 C9 34.95 5.86 
P10 45.05 4.5 C10 49.8 4.11 
P11 51.5 3.98 C11 46.15 4.44 
P12 43.2 4.74 C12 34.9 5.87 
P13 25.55 8.01 C13 13.65 15 
P14 76.9 2.66 C14 31.5 6.5 
P15 28.6 7.16 C15 60.55 7.16 
P16 50.2 4.08 C16 23.3 8.79 
P17 80.55 2.54 C17 41.6 4.92 
P18 39 5.25 C18 37.8 5.41 
P19 29.4 6.06 C19 38.1 5.37 
P20 33.8 6.96 C20 36.65 5.58 
Average 39.77  Average 34.66  
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Appendix 5: Compensation matrix  
 
Table A5: Compensation matrix determined from single stain antibody tubes. 
 CD16 CD56 CD19 7AAD CD14 CD4 CD8 CD3 CD25 CD45 
FITC  4.8   0.3     0.5 
PE 20  8  1.7      
ECD 6 41   0.8      
7AAD 1 8 23  0.1      
PE-Cy7  2 4    0.5 1   
APC       0.2 10.5   
A700     0.7 28.5  12.48   
APC-
A750 
    7 40 24.7    
BV421     0.1     1 
KRO 2.5 4.5   0.1    4.4  
 
